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Liver fibrosis is a chronic disorder that leads to accumulation of excessive amounts of 
extracellular matrix (ECM), and the first part of my dissertation work is about the effect of 
microRNA miR-29a in inhibiting the ECM gene expression at post-transcriptional or 
translational level. Our data indicates that transfection of hepatic stellate cells (HSCs) with miR-
29a significantly inhibited the expression of ECM-related genes, which was mediated by the 
putative targeting sites at their 3’-UTR. We have also found that miR-29a plays a role in 
mediating the antifibrotic effect of the nuclear receptor Farnesoid X receptor (FXR). In addition, 
we have uncovered that miR-29b indirectly inhibits ECM synthesis at post-translational level. By 
targeting the 3'-UTR of Heat shock protein 47 (HSP47) and lysyl oxidase (LOX) which are 
known to be essential for post-translational modification of ECM proteins, overexpression of 
miR-29b led to abnormal ECM structure as shown by electron-microscopy.  
The second part of my work was to improve the therapeutic outcome via formulation 
strategy. A drug-interactive motif (Fmoc) was introduced into the PEG5K-VE2 micelle system 
(PEG-FVE2), and the drug loading capacity was evaluated using paclitaxel (PTX) as a model 
drug. The Fmoc/PTX physical interaction was demonstrated by a fluorescence quenching assay. 
PTX-loaded PEG-FVE2 micelles exerted higher antitumor effect than the Taxol formulation both 
in vitro and in vivo. 
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Yifei Zhang, PhD 
University of Pittsburgh, 2014
 
 V 
As an overall approach, the targeting efficiency of drug carriers was further improved by 
conjugation with a ligand for the Sigma-2 receptor, which is over-expressed in multiple types of 
solid tumors. SV119 is a synthetic small molecule which binds to sigma-2 receptors with high 
affinity and specificity. The final part of my study showed that incorporation of SV119-PEG-
DOA significantly increased the cellular uptake of liposomes by tumor cells but not normal cells. 
This study suggests that SV119-modified liposomes might be another promising drug carrier for 
tumor targeted drug delivery. 
In summary, our study suggests that miR-29 holds potential as a novel therapeutic agent 
for the treatment of liver fibrosis. In addition, we have developed a novel formulation that 
enhances the therapeutic efficacy of existing anticancer agents such as paclitaxel. 
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1.0  INTRODUCTION  
1.1 INTRODUCTION ABOUT LIVER FIBROSIS AND MIRNA 
1.1.1 AN OVERVIEW OF LIVER FIBROSIS 
Liver fibrosis or cirrhosis is a serious problem worldwide. It ranks as the seventh leading cause 
of death in the United States. This advanced form of chronic liver disease is a result of 
pathological response to initial liver injuries of various causes, such as viral infections, drug 
overdoses, alcohol abuses, or bile-duct obstruction, and so on (Vitaglione et al. 2004, Chua et 
al. 2005, Prescott et al. 2005, Popov et al. 2009). The development of this chronic disease is 
characterized by a complex array of biologic processes that lead to the increased production of 
extracellular matrix (ECM) (Manabe et al. 2002, Popov et al. 2009). The scar tissue slowly 
replaces the normal liver tissue, leading to the loss of normal liver functions such as 
metabolism, detoxification, and endocrine functions (Triger et al. 1988). These fibrotic changes 
also lead to increases in intrahepatic vascular resistance and the development of portal 
hypertension (Thabut et al. 2010). 
The mechanism of the pathogenesis of liver fibrosis is complicated and may differ 
dependent on the underlying etiology (Bataller et al. 2005). However, transactivation of hepatic 
stellate cells (HSCs) plays an important role in the development of liver fibrosis (Zhao et al. 
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2012). Hepatic stellate cells are located in the perisinusoidal space of Disse. Under quiescent 
condition, HSCs store 80% of the total body’s vitamin A within their cytoplasm. Liver injury 
triggers the initiating and subsequent perpetuating signals that activate the quiescent HSCs (Ye 
et al. 2007). Initiating signals include oxidative stress signals, apoptotic bodies, TLR4 ligands 
(lipopolysaccharide) and paracrine stimuli from neighboring Kupffer cells, sinusoidal 
endothelial cells, and hepatocytes. These lead to the transformation of HSCs into proliferating, 
myofibroblast-like cells (Ghiassi-Nejad et al. 2008). They also gain several new phenotypes, 
such as enhanced cell migration and adhesion, expression of a-smooth muscle actin (a-SMA), 
loss of retinoid storing capacity, and, most importantly, acquisition of fibrogenic capacity 
(Friedman 2008). The buildup of excessive ECM proteins leads to fibrotic liver with impaired 
organ function (Friedman 2008). In addition to the pro-fibrogenic activities, activated HSCs 
acquire contractile property and respond to various vasoconstrictors, particularly endothelin-1 
(ET-1), which contributes to the reduction of sinusoidal blood flow and the development of 
portal hypertension (Iwakiri 2012). A number of therapies are currently being tested in the 
clinic and these include angiotensin II antagonists, interferon-g, PPAR-g ligands, and drugs that 
inhibit collagen synthesis (pirfenidone) or secretion (colchicine) (Rockey 2008).  
1.1.2 RNA interference and liver fibrosis 
1.1.2.1 siRNA and miRNA for RNA interference  
Over the past few years, studies of small RNAs have exploded and gained increasing attention. 
It is apparent that small RNAs play a very significant role in various biological processes (Liao 
et al. 1995, Sage et al. 1997, Suzuki et al. 2005). These tiny RNAs (21–26 nt) include short 
interfering (si) RNAs, microRNAs (miRNAs), heterochromatic siRNAs, tiny noncoding RNAs 
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and small temporal (st) RNAs (Lau et al. 2001, Poy et al. 2004, Sugiyama et al. 2005). SiRNA 
and miRNA are central to RNA interference (RNAi), which can modulate mRNA and protein 
expression (Kutter et al. 2008). 
SiRNAs are a class of dsRNA molecules, typically 20–25 nucleotides in length, and play 
a variety of roles in biology (Coburn et al. 2003, Sioud 2004). SiRNAs were originally 
discovered as an important gene-silencing mechanism in plants (Agrawal et al. 2003). Shortly 
thereafter, specific gene silencing was demonstrated in mammalian cells with synthetic siRNAs 
(Zhou et al. 2002b). SiRNAs have a well defined structure: a short (usually 21-nt) dsRNA with 
2-nt 3' overhangs on either end. Each strand has a 5' phosphate group and a 3' hydroxyl (-OH) 
group (Vargason et al. 2003). This structure is the result of processing by dicer, an enzyme that 
converts either long dsRNAs or small hairpin RNAs (shRNAs) into siRNAs (Paddison et al. 
2004). Synthetic siRNAs can also be exogenously introduced into cells by various transfection 
methods to bring about the specific knockdown of a gene of interest (Walters et al. 2002). Each 
siRNA is unwound into two single-stranded (ss) ssRNAs, namely the passenger strand and the 
guide strand. The passenger strand will be degraded, and the guide strand is incorporated into 
the RNA-induced silencing complex (RISC). When the guide strand base pairs with a 
complementary sequence of a mRNA molecule, Argonaute, the catalytic component of the 
RISC complex, will be able to cleave RNA, leading to post-transcriptional gene silencing. In 
essence, any gene whose sequence is known can be targeted with an appropriately designed 
siRNA. This has made siRNAs an important tool for gene function and drug target validation 
studies in the postgenomic era. 
MiRNAs are short RNA molecules with an average length of about 22 nucleotides 
(Ambros 2001). Mature miRNAs are post-transcriptional regulators that promote messenger 
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RNA transcripts (mRNAs) degradation and gene silencing or translational repression by 
annealing to complementary sequences in mRNA 3’-untranslated regions (3’-UTR) (Grosshans 
et al. 2002). In the human genome, over 1000 miRNAs have been reported, which may target 
20–30% of all human mRNAs and regulate many major processes such as development, 
apoptosis, cell proliferation, immune response, and tumorigenesis (Perera et al. 2007). 
MiRNAs are found in almost all species such as viruses, rats, mice and humans (Taccioli 
et al. 2009). Some of them lie in the introns of protein and nonprotein coding genes or even in 
exons of long nonprotein-coding transcripts, and are regulated together with their host genes 
(Mattick et al. 2005); others are found in intergenic regions, which contain their own miRNA 
gene promoter and regulatory units (Lai 2002). MiRNA genes are usually transcribed by RNA 
polymerase II (Pol II) as a huge double-stranded primary transcript (pri-miR) (Lee et al. 2004a). 
Pri-miR is recognized by a nuclear protein known as DiGeorge Syndrome Critical Region 8 
(DGCR8 or “Pasha” in invertebrates), which is associated with the enzyme Drosha to form the 
“Microprocessor” complex (Kadener et al. 2009). In this complex, pri-miR is converted into a 
double-stranded miRNA precursor of 70 nucleotide (pre-miR), which is then transported into 
the cytoplasm by a mechanism involving the nucleocytoplasmic shuttle Exportin-5. Finally, 
Dicer enzyme processes the pre-miR into the 22-nucleotide doublestranded mature miRNA. 
Although either strand of the duplex may potentially act as a functional miRNA, only the 
leading strand (the “guide strand”) is incorporated into the RISC, binding to the 3’-UTR of 
target mRNAs causing a block of translation or mRNA degradation depending on the level of 
complementarity (Moss 2002, Karkare et al. 2004, Lee et al. 2004b). 
Figure 1 shows the biogenesis of siRNA and miRNA and their mechanisms of action in 
RNAi. The similarities and differences between the two are summarized in Table 1. Given  
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Table 1 Comparison of miRNA and siRNA. 
 miRNA siRNA 
Origin of discovery Mammalian cells Plant, virus 
Length (bases) 21-28 21-25 
Synthesis Endogenous Endogenous or exogenously derived 
from virus/ chemically synthesized 
Mode of action Inhibition of 
translation 
(major)/mRNA 
degradation 
mRNA degradation (major)/chromatin 
condensation and methylation 
Location of targeting sequence 3’-UTR Coding sequence (can be anywhere) 
Source of synthesis Double-stranded 
segments of 
matched mRNA 
An unmatched segment of mRNA 
precursor featuring a hairpin turn 
Synthesis enzymes Dicer same 
Match sequence 7-8 base-pair 
“seed” match 
19-21 base-pair 
Specificity Low (target several 
genes) 
High (one gene/each) 
Detectable in cells Yes No (most of time) 
Expression regulated in cells Yes No (most of time) 
Significance in disease 
diagnosis 
Yes No 
Significance in prognosis Yes No 
Application in gene therapy Yes Yes 
 
1.1.2.2 RNAi of Liver Fibrosis via siRNA/shRNA  
There has been considerable interest in using siRNA to treat liver fibrosis in recent 
years. Most of the targeted genes are those critical for HSC activation, proliferation and/or 
collagen synthesis and deposition, which are markedly upregulated during hepatic fibrogenesis, 
including CTGF, TGF-β1, PDGF, tissue inhibitor of metalloproteinases (TIMPs) and 
plasminogen activator inhibitor-1 (PAI-1). 
One of the promising targets is TGF-β1. As a very potent ECM production stimulator 
and activator of HSCs, TGF-β1 is believed to be the key pro-fibrogenic factor in liver fibrosis. 
Studies aiming at disrupting TGF-β1 signaling pathway have shown promising effects on the 
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attenuation of liver fibrosis in experimental animal models. Lang et al. designed siRNA 
specifically targeting TGF-β1. TGF-β1 siRNA treatment group (0.125 mg/kg) showed 
significant reduction of pathological changes and mRNA and/or protein expression of TGF-β1, 
type I collagen and type III collagen (Lang et al. 2011). 
Jin’s group designed CTGF siRNA and examined its effect on the liver fibrosis model 
induced by CCl4 and ethanol (Li et al. 2006). They found that CTGF expression was reduced by 
intraportal vein injection of CTGF siRNA. Long-term treatment with this siRNA markedly 
attenuated the induction of CTGF, type I, III collagen, laminin, TIMP-1 and TGF-β1 genes, all 
of which are related to the development of liver fibrosis. 
It is believed that liver fibrosis develops as a loss of the balance between ECM 
production, deposition and ECM degradation. Targeting genes affecting matrix degradation 
could also provide another therapeitic opportunity. One of those genes is plasminogen activator 
inhibitor-1 (PAI-1), the key inhibitor of both uPA and tissue-type plasminogen activator (tPA). 
PAI-1 is a powerful pro-fibrotic molecule and is a promising therapeutic target for fibrotic 
diseases. The study from Xie et al. has shown that an adenoviral expression vector for PAI-1-
specific shRNA shows protective effect on hepatocytes and ameliorates liver fibrogenesis in 
rats. The treatment has led to the correction of the levels of matrix metalloproteinases (MMPs) 
and its inhibitors (TIMPs) through upregulation of MMP9 and MMP13, as well as 
downregulation of TIMP-1 (Hu et al. 2009). 
TIMP-2, a specific inhibitor of MMP2, has a strong correlation with the progression of 
liver fibrosis. In CCl4-treated rats, hepatic fibrosis was markedly attenuated by the 
administration of siRNA against TIMP-2, through upregulation of MMP activity. In addition to 
a reduction in collagen deposition, fewer HSCs were activated in the treatment group. 
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To date, siRNA-based therapy for liver fibrosis remains at the stage of preclinical study. 
Several issues need to be addressed before it can be translated into clinical application. One of 
them is the potency. Liver fibrosis is caused by multiple factors and various mechanisms are 
involved in the initiation and progression of this disease. Downregulation of a single gene or 
protein may not be sufficient to achieve therapeutic benefit. Other practical issues include lack 
of a suitable delivery system that specifically targets HSCs, off-target effects of siRNA, and the 
chronic nature of the disease. Targeted delivery of siRNA to the liver or specific cell population 
especially HSCs is therefore an important strategy to reduce possible adverse effects and 
improve therapeutic efficacy.  
1.1.2.3 RNAi of Liver Fibrosis via miRNAs  
MiRNAs have been shown to be critically involved in various steps of liver fibrosis. 
Roderburg and colleagues systematically analyzed the regulation of miRNAs in CCl4- and 
common bile duct ligation (CBDL)-induced liver fibrosis in mice by gene array analysis. They 
revealed a panel of miRNAs that were dysregulated in livers of mice undergoing hepatic 
fibrosis (Roderburg et al. 2011). MiR-29 family is one of those that were significantly 
downregulated in both fibrotic models. MiR-29 is encoded in two separate genomic loci 
yielding four mature miRNAs (29a, 29b1, 29b2, and 29c) (Chau et al. 2011). All members of 
the miR-29 family play a critical role in the regulation of various types of ECM proteins such as 
COL1A1, COL3A1, fibrillin and elastin as shown by us and others (Li et al. 2011a). One major 
mechanism for miR-29-mediated regulation of these fibrosis-related genes is through direct 
binding to their target sequences located at the 3'-UTR of these mRNAs. Interestingly, several 
molecules that are critically involved in collagen maturation, such as LOX and HSP47, are the 
putative targets of miR-29 (Jha et al. 2011). Therefore, miR-29 may regulate ECM expression 
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in a coordinated fashion through inhibiting ECM production at both translational and 
posttranslational steps. 
Downregulation of miR-29 members has been implicated in various fibrotic diseases 
including cardiac fibrosis, lung fibrosis, and liver fibrosis (Cushing et al. 2011). MiR-29 
members appear to be negatively regulated by NF-κB and TGF-β pathways and downregulation 
of miR-29 seems to be a major mechanism for NF-κB- and TGF-β-mediated fibrotic activity 
(Roderburg et al. 2011). 
MiR-29 represents a promising therapeutic option for the treatment of various fibrotic 
diseases including liver fibrosis. Success of this therapy is largely dependent on the 
development of a delivery system for efficient delivery of miR-29 to target cells. Alternatively, 
strategy can be developed to induce miR-29 expression in target cells. We recently showed that 
miR-29a expression in HSCs can be induced by ligands for farnesoid X receptor (FXR). FXR 
(NR1H4) is a member of the nuclear receptor superfamily that is highly expressed in liver, 
kidney, adrenals, and intestine (Anisfeld et al. 2005). FXR plays a key role in the homoeostasis 
of cholesterol and bile acids and FXR ligands have been developed for the treatment of 
cholestasis (Eloranta et al. 2008). Several studies including our own have identified a number of 
additional novel functions for FXR including antidiabetic, antihyperlipidemic, antihypertensive, 
and anti-inflammatory effects (He et al. 2006, Li et al. 2007, Zhang et al. 2008, Ge et al. 2011). 
Recently, treatment with FXR ligands has been shown to prevent liver fibrosis in rodent 
models (Jiang et al. 2007, Wang et al. 2009b, Fuchs 2012). However, the mechanism of the 
FXR ligand-mediated antifibrotic effect remains incompletely understood. The study from 
Fiorucci et al. suggested that FXR/FXR ligands inhibit the fibrotic activity in HSCs through 
SHP-mediated suppression of NF-kB and/or TGF-b signaling pathways (Fiorucci et al. 2004). 
 10 
Our recent study suggests that FXR-mediated induction of miR-29a may be a new mechanism 
for FXR/FXR ligands-mediated antifibrotic effect (Li et al. 2011a). FXR may directly induce 
miR-29a expression through binding to a putative FXR responsive element in the regulatory 
region of miR-29a gene as shown in our recent study (Li et al. 2011a). FXR may also induce 
miR-29a expression indirectly through blocking the NF-κB- and/or TGF-β-mediated 
suppression of miR-29a. Better understanding of the mechanism involved in the transcriptional 
upregulation of miR-29 gene expression may lead to the development of better strategy for the 
treatment of liver fibrosis through modulation of miR-29 expression in HSCs. 
MiR132 expression has also been shown to be lost with transactivation of HSCs. 
MiR132 appeared to be critically involved in the regulation of methyl-CpG binding protein 2 
(MeCP2) and downregulation of miR132 was associated with significant upregulation of 
MeCP2 in activated HSCs (Mann et al. 2011). This seemed to play an important role in the 
suppression of the expression of PPARγ, an important negative regulator of HSC 
transactivation. Reintroduction of miR132 into activated HSCs led to diminished MeCP2 
protein expression and elevated levels of PPARγ transcript (Mann et al. 2011). 
In addition to miR-29 and miR-132, a number of other miRNAs have been shown to be 
involved in the development of liver fibrosis. By using microarray, Zhu’s group found that 16 
miRNAs were upregulated and six miRNAs were downregulated in the fibrotic liver tissues 
from dimethylnitrosamine treated rats (Li et al. 2011b). Amongst them, rno-miR-34a, rno-miR- 
34b and rno-miR-34c were found to be the most upregulated, with a 30~130-fold increase in 
their expression levels over those of controls. Additionally, seven miRNAs were progressively 
downregulated as liver fibrosis progressed. Rno-miR-378, rno-miR-193 and rno-miR-878 were 
the three most downregulated, with an approximately two to eight-fold decrease in their 
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expression levels as compared with controls. One of the target genes of miR-34 family is 
ACSL1, which plays a central role in lipid and fatty acid metabolism in liver (Li et al. 2011b). 
In another microarray study, the expression levels of 11 miRNAs were consistently 
upregulated in CCl4-treated mice compared to the control mice, including mmulet- 7e, miR-
125-5p, 199a-5p, 199b, 199b*, 200a, 200b, 31, 34a, 497, and 802. Overexpression of miR-199a, 
miR-199a*, miR-200a and miR-200b in LX-2 cells resulted in a significant induction of several 
fibrosis-related genes compared with a control miRNA (Murakami et al. 2011). TGFβ-induced 
factor (TGIF) and SMAD specific E3 ubiquitin protein ligase 2 (SMURF2), both of which are 
negative regulators for TGF-β signaling pathway, are candidate targets of miR-199a* and miR-
200b, respectively, as determined by the Targetscan algorithm (Murakami et al. 2011). The 
study by Guo et al. showed that overexpression of miR-16 and miR-15b inhibited the 
proliferation of HSCs and induced apoptosis of these cells by downregulating the 
mitochondrial-associated antiapoptotic protein Bcl-2, leading to the activation of caspases 3, 8, 
and 9 (Guo et al. 2009). Ji’s group showed that inhibition of miR-27a and miR-27b was capable 
of reversing the activated HSCs to quiescent state, with restored cytoplasmic lipid droplets and 
decreased cell proliferation (Ji et al. 2009). 
MiR-122, as a liver specific miRNA, also plays an important role in the development of 
liver fibrosis. Our group has demonstrated that miR-122 expression is significantly 
downregulated in mouse fibrotic liver (unpublished data). Prolyl 4-hydroxylase, alpha 
polypeptide I (P4HA1) is one of the target genes of miR-122. Through downregulation of 
P4HA1, miR-122 overexpression may modulate post-translational modification of several 
collagen genes, which may lead to inhibition of collagen maturation and suppression of collagen 
production. 
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Studies have shown that liver fibrosis is associated with liver cancer. Major risk factors 
for hepatocellular carcinoma include HBV or HCV infection, alcoholic liver disease, and 
nonalcoholic fatty liver disease. Most of these risk factors can also cause the formation and 
progression of cirrhosis, which is present in 80 to 90% of patients with hepatocellular 
carcinoma (El-Serag 2011). It was reported that the 5-year cumulative risk for the development 
of hepatocellular carcinoma in patients with cirrhosis ranges between 5% and 30%, depending 
on the cause (with the highest risk among those infected with HCV), region or ethnic group 
(17% in the United States and 30% in Japan), and stage of cirrhosis (with the highest risk 
among patients with decompensated disease) (Fattovich et al. 2004). Therefore, the aim of the 
second part of my dissertation work is to develop effective treatment strategies for cancer 
therapy. We focus on the development of new strategies that enhance the performance of 
micellar and liposomal formulations as these carriers have been widely used for the delivery of 
various types of anticancer agents. 
1.2 POLYMERIC MICELLES AS NANOCARRIERS FOR CANCER TARGETED 
DRUG DELIVERY 
Polymeric micelles represent an effective delivery system for poorly water-soluble anticancer 
drugs. With small size (10-100 nm) and hydrophilic shell of PEG, polymeric micelles exhibit 
prolonged circulation time in the blood and enhanced tumor accumulation. In this chapter, the 
importance of rational design was highlighted by summarizing the recent progress on the 
development of micellar formulations.  Emphasis is placed on the new strategies to enhance the 
drug/carrier interaction for improved drug loading capacity. In addition, the micelle-forming 
 13 
drug-polymer conjugates are also discussed which have both drug-loading function and 
antitumor activity. 
1.2.1 Introduction 
Chemotherapeutic agents are typically water-insoluble, and their therapeutic outcome is 
compromised by the short circulation time and systemic toxicity. During the past century, 
tremendous efforts have been made to circumvent these limitations and improve the therapeutic 
benefit of anticancer therapeutics. This was originated from the concept of “magic bullet” that 
was proposed by Paul Ehrlich, recipient of the Nobel Prize for Physiology or Medicine in 1908, 
which suggests the benefit of targeted delivery of drug to the diseased cells. In the past decades, 
nanocarriers have emerged as an attractive research field in cancer therapy, including 
liposomes, micelles and nanoparticles made of various materials. Polymeric micelles are 
extensively studied carriers for the delivery of poorly water-soluble drugs. By enhancing the 
aqueous solubility and prolonging the half-life of chemotherapeutic agents, the anticancer 
agents can passively accumulate in tumor site through the leaky vasculature by the enhanced 
permeability and retention (EPR) effect (Gao et al. 2002, Nie et al. 2007). Compared with other 
drug carriers, micelles have the advantages of being small in size (10-100nm), which is critical 
for passive targeting to solid tumors, particularly the poorly vascularized ones  (Davis et al. 
2008). 
Based on the type of intermolecular forces driving the micelle formation, block 
copolymer micelles can be divided into several categories including hydrophobically assembled 
amphiphilic micelles, polyion-complex micelles, and micelles stemming from metal 
complexation (Gaucher et al. 2005). The hydrophobically assembled micelles usually consist of 
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amphiphilic macromolecules that have distinct hydrophobic and hydrophilic domains, and the 
commonly used block segments of copolymers have been summarized (Sutton et al. 2007). 
Upon exposure to aqueous medium, the amphiphilic molecules are spontaneously self-
assembled into supramolecular core/shell structures, and water-insoluble drugs can be loaded 
into the hydrophobic cores.  
Micelles have demonstrated a variety of shapes such as spheres, rods, vesicles, tubules 
and lamellae depending on the relative length of hydrophobic/hydrophilic blocks as well as 
solvent environment (Yu et al. 1998, Shen et al. 1999, Choucair et al. 2003). Morphology of 
micelles has significant impact on the pharmacokinetic properties of micelles. For example, 
worm-like filomicelles have shown ten times longer circulation time compared with the 
spherical counterpart made of similar material (Geng et al. 2007). 
The most commonly used hydrophilic segment of micelles for drug delivery is poly 
(ethylene glycol) (PEG), with a molecular weight of 2-15 kD. PEG is highly water-soluble, non-
toxic and neutrally charged. PEG forms a hydrophilic corona on the surface of micelles which 
minimizes the nonspecific interaction with blood components and prolongs the circulation time. 
Besides PEG, other polymers including poly(N-vinyl pyrrolidone) (PVP) (Benahmed et al. 
2001) and poly(N-isopropyl acrylamide) (pNIPAM) (Chung et al. 1998) have also been used as 
hydrophilic portion of micelles.  
Most polymeric systems involve the use of polymers as the hydrophobic domain 
including polyesters such as poly(lactic acid) (PLA) and polyamides such as poly (L-lysine) 
(PLL) and poly (beta-amino ester). Biocompatibility and biodegradability are two important 
prerequisites in designing these micellar carriers for clinical application. Polyesters and 
polyamides undergo enzyme-catalyzed hydrolysis in vivo and thus are considered 
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biodegradable. Several polymer micelle systems that have been studied clinically (Kim et al. 
2010b). For example, Genexol-PM, a polymeric micelle formulation of paclitaxel, was 
evaluated in a phase I study in patients with advanced malignancies with emphasis on 
pharmacokinetics evaluation (Kim et al. 2004). Phase II clinical trial of Genexol-PM was 
performed in patients with metastatic breast cancer (Lee et al. 2008) and advanced non-small-
cell lung cancer (Kim et al. 2007). Some other micellar formulations also have their phase I 
clinical trial completed, including paclitaxel-incorporated micellar formulation, NK105 
(Hamaguchi et al. 2007), pluronic polymer-bound doxorubicin (SP1049C) (Danson et al. 2004) 
and NK911, a micelle-encapsulated doxorubicin (Matsumura et al. 2004). 
Another type of polymeric micelles that have been investigated involve the use of lipids 
as the hydrophobic core. For example, Torchilin’s group has synthesized several PEG-
diacyllipid conjugates, in which the hydrophobic segments are lipids of various acyl chains such 
as phosphatidylethanolamine (PEG-PE) (Trubetskoy et al. 1995). Due to the strong hydrophobic 
interactions between the double acyl chains (Lukyanov et al. 2004), the PEG-PE conjugates can 
form stable micelles with very low CMC value (~10−5 M) (Musacchio et al. 2009). These 
micelles can solubilize many types of poorly water-soluble drugs including paclitaxel (Gao et 
al. 2002), tamoxifen (Gao et al. 2002), porphyrin (Gao et al. 2002), camptothecin (Mu et al. 
2005a), and vitamin K3 (Wang et al. 2004). The PEG-PE micelles exhibit favorable stability, 
longevity in blood and tumor accumulation via the EPR effect (Lukyanov et al. 2002, Lukyanov 
et al. 2004). In contrast to liposomes (Parr et al. 1997), the small size of micelles enables them 
to effectively penetrate the vasculature of tumors, even for those with very low cutoff size 
(Weissig et al. 1998).  
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Recently, Lam and colleagues have developed a series of micellar systems composed of PEG-
cholic acid (CA) conjugates (Xiao et al. 2009). A conjugate of eight CA molecules with one 
PEG5000 chain (PEG5K-CA8) was shown to load paclitaxel with high loading capacity (7.3 mg 
paclitaxel/mL) and a size of 20-60 nm (Xiao et al. 2009). These paclitaxel-loaded PEG5K-CA8 
micelles achieved improved anti-tumor effect and showed less toxicity in murine models of 
ovarian cancer compared to Taxol® and Abraxane® at equivalent paclitaxel doses (Xiao et al. 
2009). Phase I clinical trial of paclitaxel-loaded PEG5K-CA8 micelles demonstrated the 
superior anticancer efficacy and tolerance (Xiao et al. 2011). In addition, compared to PEG5K-
CA8 micelles, a similar micellar carrier PEG2K-CA4 was demonstrated to have higher 
doxorubicin loading capacity and more sustained drug release profile (Xiao et al. 2011). 
 
The last decade has seen significant progress in the development of various micellar systems for 
targeted delivery of anticancer agents (Liu et al. 2006, Sutton et al. 2007, Torchilin 2007). 
However, much improvement is still needed for the existing systems with respect to drug 
loading capacity and formulation stability. Despite the structural differences among the reported 
micellar systems, most of them mainly rely on hydrophobic/hydrophobic interaction for drug 
incorporation into the hydrophobic cores. Such mechanism, while working well for some highly 
lipophilic drugs, may not provide sufficient drug/carrier interaction to effectively load other 
drugs. Various strategies have been proposed to introduce additional drug-interactive domains 
into the micellar system to improve the overall carrier/drug interaction.  In addition, progress 
has been made in developing dual-functional carriers that demonstrate both delivery function 
and antitumor activity. The following two sections will summarize some of the works from our 
lab and other labs in  developing improved micellar systems for anticancer agents. 
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1.2.2 MICELLES WITH BUILT-IN DRUG-INTERACTIVE DOMAIN AS IMPROVED 
DELIVERY SYSTEMS FOR ANTICANCER AGENTS 
The drug loading capacity of polymeric micelles is critically dependent on the 
compatibility between the drug and the micelle core (Latere Dwan'Isa et al. 2007). A series of 
studies have demonstrated that the drug loading capacity of micelles can be greatly enhanced by 
optimizing chemical structures of the inner core segment for stronger drug-carrier interaction. A 
typical example of the strategy for enhanced compatibility between drug and block copolymer 
is the development of hydrotropic polymers. Hydrotropy refers to a phenomenon that the 
aqueous solubility of a poorly soluble compound is significantly enhanced by the presence of 
large amounts of a second solute, named hydrotrope (Coffman et al. 1996). The hydrotropes 
aggregate only above a certain concentration, which is known as the minimal hydrotrope 
concentration (MHC) (Bauduin et al. 2005). Various studies have been carried out to elucidate 
the process of hydrotropic solubilization. Although the exact mechanism is not fully clarified, it 
may involve multiple non-covalent interactions including hydrophobic interaction, hydrogen 
bonding (Kim et al. 2010a) as well as parallel stacking effect (Ooya et al. 2006, Cui 2010).  
Most of the hydrotropes include an aromatic ring substituted by heteroatoms. The 
aromatic rings are basically hydrophobic, which can stack with each other or with the benzene 
rings in drug molecules (Landauer et al. 1952). In addition, the polar groups may interact with 
drugs via hydrogen bonding (Charman et al. 1993). For example, nicotinamide, a typical 
hydrotrope, has been shown to form complex with various hydrophobic drugs and enhance their 
water solubility (Rasool et al. 1991). It has a pyridine ring that promotes the π-π stacking with 
drug molecules through its planarity (Sanghvi et al. 2007). In addition, self-association of 
nicotinamide was shown to play a major role in the hydrotropic solubilization of riboflavin 
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instead of complexation between the two species (Coffman et al. 1996). Another example is 
N,N-diethylnicotinamide, which was shown to be the most effective hydrotrope for solubilizing 
paclitaxel among more than 60 structures tested (Lee et al. 2003). One drawback of hydrotropic 
solubilization is that high concentration of hydrotrope is usually required, which may cause 
various side effects. This is due to the high MHC of usual hydrotropes of about 1 M, compared 
to the critical micelle concentration (CMC) of typical micelles at 10-2-10-3 M (da Silva et al. 
1999). To overcome this barrier, hydrotropic polymers have been developed which can 
dramatically enhance the local concentration of hydrotropes. Park’s group has synthesized PEG 
block co-polymers with hydrotropes linked with the hydrophobic domain of polymeric micelles, 
which appeared to be a versatile strategy to enhance the water solubility of various hydrophobic 
drugs of different structures (Huh et al. 2005, Kim et al. 2011). The key factors that affect the 
performance of hydrotropic polymers include the polymer backbone, type and orientation of 
hydrotropic moieties and the spacer groups connecting the backbone and hydrotropes. The 
review by Ooya et al. provides a comprehensive summary of the studies regarding the structure-
activity relationship of hydrotropic polymers (Ooya et al. 2006). 
Besides hydrotropic effect, additional non-covalent interactions have been employed to 
improve drug loading in polymeric micelles. For example, modification of poly(ethylene 
glycol)-poly(beta-benzyl L-aspartate) (PEG-PBLA) block copolymer with benzyl ester on the 
PBLA chain enhanced the loading efficiency and stability of camptothecin-loaded micelles 
(Opanasopit et al. 2004).  Incorporation of hydrogen-bonding urea-functional groups into block 
copolymers led to decreased CMC and improved stability of doxorubicin-loaded micelles (Kim 
et al. 2010c).  Similarly, the stability of micelles was enhanced with increased number of 
acid/urea groups in the micelles, which was due to improved hydrogen-bonding between the 
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carrier molecules and acid-amine ionic interaction between the drug and carrier (Yang et al. 
2012a). In addition, the loading of indomethacin and ibuprofen into polymeric micelles was 
dramatically improved by the acid-base interaction between hydrophobic segments of micelles 
and guest molecules containing carboxylic acid groups (Giacomelli et al. 2007). Furthermore, 
Kataoka’s group has shown that the encapsulation of cisplatin into polymeric micelles was 
facilitated by metal-ligand coordination (Yokoyama et al. 1996, Nishiyama et al. 2001). 
Inclusion of aromatic end groups (e.g. benzoyl and naphthoyl) has also been shown to improve 
the loading of paclitaxel into mPEG750-b-oligo(epsilon-caprolactone)5-based oligomeric 
micelles (Carstens et al. 2008).   
We have recently demonstrated that the introduction of Fmoc as a “drug-interactive 
domain” can also significantly improve the drug-loading capacity of both emulsion and lipid-
core micellar system (Gao et al. 2013). A series of PEGylated lipopeptide surfactants were 
designed and constructed to solubilize a synthetic antioxidant, JP4-039. Several ε-Boc-lysine 
derivatives with various protective groups at α-NH2 position were tested for their ability to 
solubilize JP4-039, among which the α-Fmoc-ε-Boc lysine was shown to be the most potent one 
(Gao et al. 2013). Incorporation of this drug-interactive motif Fmoc into drug-loaded emulsion 
led to significant increase in the formulation stability. We then designed another polymer-based 
micelle system, in which the Fmoc motifs were located at the interfacial region of lipopeptide 
surfactants with PEG5K as the headgroup and two oleoyl chains as the core-forming segment 
(Zhang et al. 2014). The PEG5K-(Fmoc-OA)2 exhibited lower CMC value and significantly 
improved loading capacity for paclitaxel compared with an analogue without Fmoc motifs. The 
paclitaxel-loaded PEG5K-(Fmoc-OA)2 micelles showed increased anticancer effect over Taxol 
in vitro and in vivo. In addition, 7 other drugs were effectively loaded into PEG5K-(Fmoc-OA)2 
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micelles, which suggests the utility and versatility of this platform for a broad range of drugs 
with different structures (Zhang et al. 2014). Although the exact mechanism of carrier-drug 
interaction is not fully understood, the hydrophobic interaction and π- π stacking effect possibly 
contribute to the compatibility between the drug and carrier. 
1.2.3 PEG-DRUG CONJUGATES AS DUAL-FUNCTION CARRIERS FOR CANCER 
TARGETED DELIVERY 
1.2.3.1 Rationale of Combination Therapy Using Polymer-Drug Conjugates as Carriers 
As discussed above, improved drug loading capacity, stability and tumor-specific 
distribution can be achieved by various strategies. However, most of the polymeric materials for 
drug delivery are “inert” and lack of therapeutic activity. In addition, the use of large amounts 
of carrier materials may impose safety concerns (Croy et al. 2006). Since Ringsdorf (Ringsdorf 
1975) proposed the concept of “polymeric prodrug” in 1975, the utility of polymer-drug 
conjugates in clinical therapy has been well demonstrated. Interestingly, the conjugate of 
hydrophobic drug with hydrophilic polymers might be self-assembled into micelles, which can 
be potentially useful for the loading of another therapeutic molecule. Drug encapsulation with a 
biologically active carrier is an attractive strategy as it represents a unique form of combination. 
Combination therapy with multiple agents working at several signaling pathways at the same 
time could not only lead to maximized anticancer effect but also help to overcome the drug 
resistance (Broxterman et al. 2005). For example, the combination of PGA-paclitaxel conjugate 
with cisplatin (Verschraegen et al. 2009) or carboplatin (Langer et al. 2008) has shown 
improved therapeutic benefits or reduced toxicity in Phase I clinical trial.  In addition, the 
anticancer effect of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin 
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conjugate in combination with HPMA copolymer-mesochlorin e6 was shown to be more 
efficacious than either conjugate alone (Shiah et al. 2001).  
In contrast to the common combination regimen, drug-loading with bioactive carriers 
ensures the simultaneous arrival of multiple therapeutic agents at the same targeting site, and 
thus represents a promising strategy for better therapeutic outcome.  These dual-function 
carriers not only deliver the drug to tumor site but also are biologically effective, which either 
enhances the therapeutic effect (Mi et al. 2011) or reduce the toxicity caused by the 
incorporated drug (Dong et al. 2005).  
However, micellar systems based on drug-polymer conjugates are rarely used for the 
physical incorporation of another hydrophobic molecule. The following section summarizes 
some of the recent works from us and others, which demonstrate that such a strategy is not only 
feasible but also effective. 
1.2.3.2 PEG-Vitamin E Conjugates as Dual-Function Carriers for Cancer Targeted 
Delivery 
D-α-tocopheryl polyethylene glycol (PEG) 1000 succinate (TPGS) is a PEG derivatized 
natural Vitamin E which has been approved by FDA as a safe pharmaceutical adjuvant for drug 
formulation. In recent years the application of TPGS in drug formulations has been extensively 
studied, such as emulsifier in Poly (lactic-co-glycolic acid) (PLGA)  nanoparticles (Mu et al. 
2002), solubilizer and permeation enhancer (Yu et al. 1999), TPGS-based liposomes (Muthu et 
al. 2011), copolymers (Zhang et al. 2006) and nanocrystal (Liu et al. 2010). By inhibiting the 
function of P-glycoprotein (P-gp), TPGS also helps to overcome the multidrug resistance 
(Dintaman et al. 1999) and enhance the oral bioavailability of anticancer drugs (Varma et al. 
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2005). In addition, TPGS-doxorubicin conjugate was developed as a prodrug for enhanced 
therapeutic effect (Cao et al. 2008). 
TPGS forms micelles in aqueous solution, which were used for the dispersion of 
functional nanostructures such as carbon nanotubes (Yan et al. 2007, Xu et al. 2010), fullerenes 
(Yan et al. 2007) and iron oxide (Chandrasekharan et al. 2011). However, with a relatively high 
critical micelle concentration (CMC) value of 0.2 mg/mL (Zhang et al. 2012), TPGS micelles 
are not stable and easily dissociated upon dilution by plasma after intravenous injection. 
Therefore, TPGS is usually used together with other excipients to form mixed micelles. For 
example, PEG-phosphatidylethanolamine (PEG-PE) was mixed with TPGS at a molar ratio of 
2:1 for the loading of camptothecin (CPT), which increased the CPT solubility by at least 50% 
compared to PEG-PE micelles without TPGS (Mu et al. 2005b). Similarly, mixed micelles of 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] 
(DSPE-PEG) with TPGS were prepared to encapsulate an anticancer agent, 17-allyamino-17-
demethoxygeldanamycin (17-AAG) (Chandran et al. 2010), resulting in controlled drug release 
and improved cytotoxicity compared with the free drug. In addition, TPGS also forms mixed 
micelles with Pluronic P105 (Gao et al. 2008), Pluronic P123 (Zhao et al. 2011) and Pluronic 
F127/poly(butyl cyanoacrylate) (PBCA) (Wang et al. 2009a). Compared with free drug or 
micelles without TPGS, those micelles showed improved solubility of hydrophobic anticancer 
drugs and increased cytotoxicity against MCF-7, MCF-7/ADR and HepG2 cell lines. 
To further facilitate the use of TPGS as a micellar formulation, several strategies have 
been developed to decrease its CMC. Feng’s group has conjugated one tocopheryl succinate 
molecule with a PEG2K chain to generate TPGS2K for the delivery of docetaxel, which showed 
much lower CMC value compared with traditional TPGS (Mi et al. 2011). This improvement 
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has enabled the formation of stable drug-loaded TPGS micelles without the help of other 
polymers or lipids. Another benefit of longer PEG chain is to further decrease the nonspecific 
uptake of TPGS2K micelles by RES. The study by Wang et al showed that a conjugate of PEG2K 
with two Vitamin E molecules exhibited further reduced CMC of 1.14 µg/mL (Wang et al. 
2012a), compared to that of TPGS2K (21.9 µg/mL) and TPGS (200 µg/mL) (Mi et al. 2011). 
Importantly, PEG2K-Vitamin E2 well retained the intrinsic activity of TPGS in inhibiting the 
activity of P-gp. Doxorubicin-loaded TPGS2K micelles showed greater cytotoxicity and tumor 
inhibitory effect than doxorubicin formulated in conventional TPGS (Wang et al. 2012a). In 
light of this information, we have recently developed four PEG-Vitamin E conjugates that differ 
in PEG molecular weight (PEG2K vs PEG5K) and the molar ratio of PEG/Vitamin E (1/1 vs 1/2), 
and their paclitaxel loading capacity was subsequently compared (Lu et al. 2013a). Our data 
have shown that among all the four conjugates, PEG5K conjugate with two Vitamin E molecules 
(PEG5K-VE2) showed the lowest CMC value, highest loading capacity and stability. All the four 
conjugates retained the P-gp inhibition activity of TPGS. Delivery of paclitaxel via PEG5K-VE2 
led to significantly improved antitumor activity compared with the commercial formulation 
Taxol® and other paclitaxel micellar formulations. 
1.2.3.3 PEG-Derivatized Embelin as a Nanocarrier for the Delivery of Paclitaxel 
Embelin is an alkyl-substituted hydroxyl benzoquinone natural product discovered from the 
Japanese Ardisia Herb (Herba Ardisiae Japonicae) (Nikolovska-Coleska et al. 2004). Embelin 
was shown to possess a broad spectrum of biological activities including anti-diabetic (Bhandari 
et al. 2007), anti-inflammatory (Chitra et al. 1994) and hepato-protective effects (Singh et al. 
2009). In addition, embelin exhibits antitumor activity in many types of cancers such as breast 
(Li et al. 2013c), colon (Dai et al. 2009), prostate (Danquah et al. 2009) and pancreatic cancer 
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(Mori et al. 2007). Through computational structure based computer screening, Wang et al 
(Nikolovska-Coleska et al. 2004) discovered that embelin is a potent inhibitor of X-linked 
inhibitor of apoptosis protein (XIAP), which partially explained its anticancer mechanism. 
XIAP is over-expressed in various types of cancer cells (Tamm et al. 2000), particularly in 
drug-resistant cancer cells (Berezovskaya et al. 2005), while it plays a minimal role in normal 
cells. Inhibition of XIAP has been demonstrated as an effective approach to selectively 
inhibiting the growth of cancer cells (Vogler et al. 2009). Embelin also inhibits NF-κB 
activation, which mediates the down-regulation of several genes including surviving, XIAP, 
IAP1/2, TRAF1, cFLIP, Bcl-2 and Bcl-xL (Ahn et al. 2007).  
Bearing a long lipophilic chain, embelin is extremely hydrophobic and water-insoluble. 
In an attempt to explore the PEG modification as an approach to increase its water solubility, 
we have found that PEG-derivatized embelin forms micelles in aqueous solution (Huang et al. 
2012). This is not a surprise considering the structural similarity between embelin with Vitamin 
E. Interestingly, the antitumor activity of embelin was well retained after coupling with PEG 
chain (Huang et al. 2012). In addition, the PEG-embelin micelles are highly efficient in 
solubilizing various types of anticancer agent such as paclitaxel (Huang et al. 2012, Lu et al. 
2013b). Furthermore, PEG-embelin, at nanomolar range, showed synergistic effect with 
paclitaxel in several cancer cell lines tested (Huang et al. 2012). In vitro and in vivo studies 
have shown that the conjugate with two embelin molecules linked with one PEG chain is 
significantly more effective for loading paclitaxel than the conjugate with a 1:1 molar ratio of 
PEG and embelin. In addition, the PEG-embelin conjugates with longer PEG chain (PEG5K) 
were shown to be more advantageous compared with the counterparts with shorter PEG chain 
(PEG3.5K) (Huang et al. 2012, Lu et al. 2013b). Near infrared fluorescence (NIRF) imaging of 
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PC-3 xenograft-bearing mice showed that PEG5K-EB2 micelles were selectively accumulated at 
tumor site with minimal distribution in major organs including liver and spleen (Lu et al. 
2013b). Delivery of paclitaxel via PEG5K-embelin2 micelles leads to superior antitumor activity 
compared to Taxol in murine models of breast and prostate cancers (Lu et al. 2013b). 
1.2.3.4 PEG-Farnesylthiosalicylate (PEG-FTS) Conjugate Micelles for the Delivery of 
Paclitaxel 
S-trans, trans-farnesylthiosalicylic acid (Salirasib, or FTS) is a synthetic antagonist of Ras 
protein. By disrupting the anchorage of Ras on cell membrane (Weisz et al. 1999), FTS is 
designed to inhibit Ras-dependent growth of cancer cells. Approximately 20 to 30% of human 
tumors express permanently active oncogenic Ras (Grewal et al. 2011), and the mutationally 
activated Ras was most commonly found in adenocarcinomas of the pancreas (90%), colon 
(50%), lung (30%), thyroid tumors (50%), and myeloid leukemia (30%) (Bos 1989, Downward 
2003). Accordingly, FTS exhibited potent antitumor effect in various tumors such as pancreatic 
cancer (Weisz et al. 1999), colon cancer (Halaschek-Wiener et al. 2000), melanoma (Jansen et 
al. 1999) and neurofibromatosis (Barkan et al. 2006). In addition, Ras inhibitors demonstrated 
synergistic effect with other chemotherapeutics, which validated their application in 
combination therapy (Blum et al. 2005). For example, treatment of the resistant SW480 cells 
with FTS dramatically enhanced the sensitivity to gemcitabine and led to improved inhibition of 
tumor growth in vivo (Gana-Weisz et al. 2002). 
Similar to Vitamin E and embelin, FTS is also a hydrophobic small molecule with a long 
hydrophobic chain and a functional group (-COOH) that can be readily used for further 
modification. The biological activity and chemical structure of FTS has prompted us to design 
the PEG-derivatized FTS conjugate as another dual-function micellar drug carrier (Zhang et al. 
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2013). A labile ester linkage was used to facilitate the release of FTS and disassembly of the 
drug-loaded micelles following intracellular delivery to tumor cells. Our data have shown that 
the PEG-FTS2 readily forms micelles in aqueous solution with a CMC of 0.68 µM. Paclitaxel 
can be efficiently loaded into those micelles, which are spherical in morphology with a uniform 
size of 20-30 nm. Ras protein down-regulation and cytotoxicity of PEG-FTS2 were comparable 
to free FTS as shown in 4T1.2 and HCT-116 cancer cell lines. The antitumor activity of 
paclitaxel-loaded PEG-FTS2 micelles was shown to be significantly higher than that of Taxol in 
a syngeneic murine breast cancer model (Zhang et al. 2013). 
1.2.3.5 Other Drug-Polymer Conjugate Micelles for the Delivery of a Hydrophobic 
Chemotherapeutics 
Several other micellar systems have been studied, which are based on polymer-drug conjugates 
such as polymer-curcumin and polymer-adriamycin conjugates. Curcumin is a natural 
polyphenol compound with promising anti-cancer application (Aggarwal et al. 2003, Wilken et 
al. 2011). It was reported that curcumin blocks NF-κB pathway (Shishodia et al. 2005) and in 
turn, induces apoptosis and inhibits the function of protein kinase C, epidermal growth factor 
receptor tyrosine kinase, and HER-2 (Sharma et al. 2005, Aggarwal et al. 2006). Curcumin has 
shown antitumor activity against various types of cancers including those of breast (Holy 2002), 
colon (Jiang et al. 1996), prostate (Holy 2004, Deeb et al. 2007), kidney (Woo et al. 2003), liver 
(Yoysungnoen et al. 2006), lymphoid and myeloid tissues (Anuchapreeda et al. 2006), and 
melanoma (Odot et al. 2004). In spite of all the anticancer activities, the potential application of 
curcumin is hindered by its poor water solubility and limited bioavailability. Furthermore, high 
drug dose is required for a desired therapeutic outcome due to its relatively low potency. 
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Therefore, nanosized delivery systems with high loading capacity and tumor-specific 
distribution represent an attractive strategy to address these issues. 
In an attempt to increase the solubility of curcumin, various formulations have been 
developed such as cyclodextrin (Yallapu et al. 2010), nanoparticles (Anand et al. 2010), 
microparticles (Shahani et al. 2011) and nano-sized complex (Zhang et al. 2011a).  Polymer-
curcumin conjugates were also synthesized as polymeric prodrugs. For example, Safavy et al. 
synthesized two conjugates including curcumin-PEG750 and curcumin-PEG3.5K (Safavy et al. 
2007). Both conjugates exhibited enhanced water solubility and cytotoxicity against several 
human cancer cell lines in comparison with free curcumin (Safavy et al. 2007). To further 
increase the drug content in the nanoparticles, Tang et al. synthesized a curcumin prodrug by 
attaching it with two short oligo (ethylene glycol) (Curc-OEG) chains. Beta-thioester bond was 
applied which can be selectively cleaved intracellularly by glutathione and esterase to release 
the drug (Tang et al. 2010). With a curcumin loading content of 25.3 wt%, the Curc-OEG 
conjugate formed stable nanoparticles in aqueous solution and exhibited dramatic anticancer 
effect in vitro and in vivo without causing significant toxicity (Tang et al. 2010). Curcumin-
polymer conjugates were also synthesized with hyaluronic acid (Manju et al. 2011a) and 
polyvinylpyrrolidone (Manju et al. 2011b). Most recently, Yang et al. (Yang et al. 2012b) 
demonstrated that the covalent curcumin-polymer conjugates can be further used to physically 
encapsulate additional curcumin. Curcumin was loaded into the polymeric micelles, which were 
synthesized by attaching multiple curcumin molecules to the hydrophobic poly (lactic acid) 
(PLA) backbone of PEG-PLA copolymer. Such micelles exhibited 10 times lower CMC value 
and dramatically enhanced curcumin loading capacity (~5 folds) compared to traditional mPEG-
PLA micelles (Yang et al. 2012b).   
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Yokoyama et al. has reported that adriamycin (ADR)-conjugated polyethylene glycol–
poly(aspartic acid) block copolymers (PEG-P[Asp(ADR)]) form micelles in aqueous solution 
and exhibited dramatic antitumor activity in vivo (Yokoyama et al. 1991, Yokoyama et al. 1992, 
Yokoyama et al. 1993). However, the ratio of chemically/physically entrapped adriamycin was 
not analyzed, and certain amounts of adriamycin derivatives were incorporated in the micelles 
as impurities, which may cause side effects (Yokoyama et al. 1994). The micelle preparation 
method was then improved which enabled the determination of this ratio and reduced the 
amounts of impurities (Yokoyama et al. 1994, Yokoyama et al. 1998). In addition, Yang et al. 
(Yang et al. 2012c) developed a dual-drug system in which doxorubicin was chemically linked 
to the PLA end of polyethylene glycol-b-poly lactic acid (PEG-b-PLA). This conjugate was 
mixed with RGD-PEG-b-PLA, PEG-b-PLA and an antivascular agent combretastatin A4 to 
prepare the micelles. This dual-drug system significantly enhanced cellular uptake of the drug 
by B16-F10 cells and human umbilical vein endothelial cells, and achieved significant 
antitumor effect with increased lifespan of tumor bearing mice. 
In summary, pharmacological evaluation and drug formulation are two of the critical 
aspects in drug development process. This project has two specific aims: (1) to develop a novel 
therapeutic agent for disease treatment; and (2) to improve the efficacy of existing therapeutics 
via novel formulation strategies. 
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2.0  ROLES OF MIR-29A IN THE ANTIFIBROTIC EFFECT OF FXR IN HEPATIC 
STELLATE CELLS 
This chapter is reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics. All rights reserved. 
Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics 
2.1 BACKGROUND 
Liver fibrosis is a chronic disorder that is characterized by an alteration of the balance between 
fibrogenesis and fibrolysis, resulting in accumulation of excessive amounts of extracellular 
matrix (ECM) and distortion of the normal liver architecture (Jiao et al. 2009). The activation 
and transformation of quiescent hepatic stellate cells (HSCs) into myofibroblast-like cells 
constitute a major mechanism for the increased production of ECM in the liver (Parsons et al. 
2007, Friedman 2008). The mechanism of HSC activation is not completely understood and 
involves the alterations of a number of intracellular pathways such as TGF-β and PDGF 
signaling (Parsons et al. 2007, Friedman 2008). Several studies have shown that nuclear 
receptors such as peroxisome proliferators-activated receptor gamma (PPAR-γ) and pregnane-X 
receptor (PXR) also play an important role in the modulation of HSC activation and their 
biological functions (Miyahara et al. 2000, Galli et al. 2002, Marek et al. 2005). 
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FXR (farnesoid X receptor, NR1H4) is a member of the nuclear receptor superfamily 
that is highly expressed in liver, kidney, adrenals, and intestine (Forman et al. 1995). FXR plays 
a key role in the homeostasis of cholesterol and bile acids (BAs) by regulating the expression of 
genes involved in the synthesis and transport of BAs (Chiang 2002, Bertolotti et al. 2008). In 
addition to the potential of its ligands in the treatment of cholestasis (Claudel et al. 2002), FXR 
has been shown to be expressed in HSCs and negatively regulate the activation of HSCs and the 
associated overproduction of ECM in rodent models of liver fibrosis (Fiorucci et al. 2004, 
Fiorucci et al. 2005a, Fiorucci et al. 2005b). A study by Fiorucci et al. suggested that short 
heterodimer partner (SHP) played a role in the FXR-mediated antifibrotic effect. SHP is one of 
the FXR target genes and it effectively blocks the AP-1 signaling that is critically involved in 
ECM production (Fiorucci et al. 2004). However, the detailed mechanism that is involved in the 
antifibrotic effects of FXR remains incompletely understood. 
MicroRNAs (miRNAs) are short non-coding RNA molecules that control gene 
expression via modulating the stability and/or the translational efficiency of target messenger 
RNAs (Lee et al. 1993, Ghildiyal et al. 2009). MiRNAs play a role in the control of a wide 
range of biological functions and processes such as development, differentiation, metabolism, 
carcinogenesis, immune response etc (Ghildiyal et al. 2009). MiRNAs are initially transcribed 
as long primary transcripts that undergo several processing steps to form the mature 22-nt 
miRNA:miRNA* duplex. The complementary strand miRNA* is typically degraded, while the 
mature single-stranded form is incorporated into the RNA-induced silencing complex (RISC). 
Most of miRNA binding sequences are found in the 3′-UTR of the mRNAs (Ghildiyal et al. 
2009). However, increasing evidence suggests that miRNAs can also be targeted to both 
coding-regions and 5′-UTR of mRNAs (Forman et al. 2008). Several studies showed that 
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miRNAs were involved in the activation of HSCs: a number of miRNAs species are upregulated 
while many others are downregulated during the process (Guo et al. 2009, Ji et al. 2009, 
Venugopal et al. 2010). A recent study by Roderburg and colleagues showed that all three 
members (a, b, and c) of the miR-29 family were significantly downregulated in mouse liver 
with CCl4 and common bile ligation induced liver fibrosis (Roderburg et al. 2011). 
Downregulation of miR-29a/b/c was also shown in activated HSCs in vitro. A likely role of 
miR-29 members in liver fibrosis is suggested by: a) overexpression of miR-29 in mouse HSCs 
led to downregulation of the expression of several ECM genes; and b) treatment with TGF-β or 
LPS-mediated activation of NF-κB signaling led to downregulation of the expression of miR-
29a/b/c (Roderburg et al. 2011). The clinical significance is further supported by the 
observation that serum levels of miR-29a in patients with cirrhosis are inversely correlated with 
the stages of the disease (Roderburg et al. 2011). The critical role of miR-29 in fibrotic diseases 
was also demonstrated in animal models of pulmonary fibrosis (Cushing et al. 2011) and renal 
fibrosis (Wang et al. 2012d). However, it is unknown if miRNAs are also involved in the 
antifibrotic effect of FXR in HSCs. 
In this study, we showed that activation of FXR by a synthetic ligand, GW4064, led to 
significant upregulation of the expression of miR-29a in mouse, rat, and human HSCs. 
Functional and reporter assays suggested that miR-29a is a potent mediator that negatively 
regulates the expression of several ECM genes. Furthermore, a functional FXR response 
element (FXRE) was found in the miR-29a promoter. Our study unveils a new mechanism by 
which FXR negatively regulates the expression of ECM in HSCs. 
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2.2 METHODS 
2.2.1 Reagents and Chemicals 
GW4064 (3-[2-[2-Chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)- 4-
isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid) was synthesized following a published 
protocol (Maloney et al. 2000). MiR-29a mimic and non-specific control miRNA mimic were 
purchased from ABI (Applied Biosystems, Foster City, CA). All products for cell culture were 
purchased from Invitrogen (Carlsbad, CA). pCMX, pCMX-FXR, and pCMV-βgal were 
described previously (Umesono et al. 1991). pCMX-vpFXR (a gift from Drs Enrique Saez and 
Ronald Evans at the Salk Institute) was generated by fusing the VP16 activation domain from 
the herpes simplex virus to the N terminus of the FXR (Downes et al. 2003). 
2.2.2 Animals and HSC Isolation 
Retired male Sprague-Dawley rats and C57BL/6 mice were from Charles River Laboratories. 
FXR-/- mice (Sinal et al. 2000) were purchased from Jackson Laboratories and bred in the 
Central Animal Facility of University of Pittsburgh. HSCs were isolated via in situ 
proteinase/collagenase perfusion followed by density gradient centrifugation as described 
(Thirunavukkarasu et al. 2005). Primary cells were more than 95% pure. Cells were grown on 
standard tissue culture plastic dishes in DMEM with 10% fetal bovine serum and antibiotics. 
HSCs were used following activation via culturing for 7 days. All studies conform to the Guide 
for the Care and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996). 
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LX-2, an immortalized human hepatic stellate cell line, was kindly provided by Dr. Scott 
L. Friedman (Mount Sinai School of Medicine, New York, NY, USA) (Xu et al. 2005). The 
cells were maintained in DMEM with 10% fetal bovine serum and antibiotics. 
2.2.3 Real Time RT-PCR 
Total RNA was extracted from cells with TRIzol reagent (Invitrogen) and the first-strand cDNA 
was synthesized by use of SuperScript III reverse transcriptase (Invitrogen). Real-time PCR 
analysis of rat, mouse, and human fibrosis-related genes and miR-29 precursor was performed 
by use of SYBR Green-based assays with the ABI 7300 Real-Time PCR System (Applied 
Biosystems, Foster City, CA) (Li et al. 2008a). Transcript abundance, normalized to β-actin 
expression, was expressed as fold increase over a calibrated sample. 
For detection of mature miRNA, total RNA was reversely transcribed into cDNA using 
miScript  Reverse Transcriptase Kit (Qiagen) according to the manufacturer’s protocol. cDNA 
samples (2 μl) were used for real-time PCR in a total volume of 25 μl using miScript SYBR 
Green PCR Kit (Qiagen) and miRNA specific primers (Qiagen) on a qPCR machine (Applied 
Biosystems, Foster City, CA). The sequences of primers for all of the RT-PCR analysis were 
shown in Appendix A. 
2.2.4 Western Blot Analysis 
Protein extraction and Western blot analysis were performed as described (Li et al. 2008a). FXR 
antibody (sc-13063) and collagen 1A1 (COL1A1) antibody (sc-25974) were purchased from 
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Santa Cruz Biotechnology. Horseradish peroxidase–labeled goat anti-rabbit IgG and the ECL 
chemiluminescence kit were purchased from Amersham Biosciences (Piscataway, NJ). 
2.2.5 Plasmid Construction 
A fragment spanning 1.98 kb of 5′-flanking sequence of the human miR-29a gene was PCR-
amplified from human genomic DNA using primers 5′-cgacgcgtgtgggtaagggagagggaag-3′ and 
5′-cgacgcgttgctgactgatgagaggaaa-3′ and cloned into Mlu1 of pGL3-basic vector (Promega). A 
mutated construct that lacks a putative IR-1 (miR-29a/IR-1) binding site was similarly 
generated via cloning a fragment spanning 1.87 kb of 5′-flanking sequence of the miR-29a gene 
that was amplified using primers 5′- cgacgcgtctggtgttcgcagctttcac-3′ and 5′-
cgacgcgttgctgactgatgagaggaaa-3′. A TK-Luc construct that contains three copies of miR-
29a/IR-1 sequence was generated by annealing the oligonucleotides 5′-
agcttcttggaggtcacagacctcgaggtcacagacctcgaggtcacagacctcgttg- 3′ and 5′-
caacgaggtctgagacctcgaggtctgagacctcgaggtctgagacctccaaga-3′ followed by ligation into 
HindIII/BamHI-digested TK-Luc. For functional analysis of miR-29a, 3′-UTR segments 
containing the miR-29a-binding sequences or without binding sequences for COL1A1, collagen 
3A1 (COL3A1), and elastin-1 (ELN1) genes were PCR amplified from human genomic DNA 
utilizing the corresponding forward and reverse primers (Appendix A). The PCR product was 
then subcloned into the SacI-MluI site downstream of the stop codon in the pMIR-REPORT 
Firefly Luciferase reporter vector (Ambion). 
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2.2.6 Transfection Assays 
Normal monkey kidney fibroblast cells (CV-1 line) were grown to 60–70% confluence in 48-
well plates. Cells were transiently transfected using Lipofectamine2000 (Invitrogen) with 
pGL3-miR-29a in the presence or absence of pCMX-vpFXR or pCMX-FXR. pCMX was added 
to ensure identical amounts of DNA in each well. Transfection efficiency was monitored by co-
transfection of pCMV-βgal plasmid. Twenty-four h later, cells were treated with GW4064 or 
DMSO vehicle. Cell extracts were prepared 24 h after GW4064 treatment and the luciferase and 
β-galactosidase assays were performed as described (He et al. 2006) and luciferase activity was 
normalized against β-galactosidase activity. Transfection experiments were performed on at 
least three occasions and in each case were done in triplicate. Data were represented as fold 
induction over reporter gene alone. In a separate study, CV-1 cells were transfected with pMIR-
COL1A1-3’-UTR, pMIR-COL3A1- 3’-UTR, or pMIR-ELN1-3’-UTR in the presence of miR-
29a mimic or non-specific control miRNA mimic. The reporter expression was then similarly 
examined as described above 24 h following transfection. 
2.2.7 Electrophoretic Mobility Shift Assay (EMSA) 
FXR and retinoid X receptor (RXR) proteins were generated in vitro by coupled in vitro 
transcription/translation (TNT system, Promega) with pCMX-FXR and pCMX-RXR plasmids. 
The DNA probe miR-29a/IR1 (5'- gaagaggtcacagacctctgg -3') was derived from a region in the 
human miR-29a promoter that contains a putative FXR response element. It was labeled with 
[γ-32P]-ATP by using the Klenow fragment of DNA polymerase. DNA-binding reactions were 
carried out as follows: aliquots of in vitro translation mixture were incubated in 20 μL binding 
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buffer (10 mM Hepes, pH 7.9, 10 mM EGTA, 10 mM EDTA, 0.25 mM DTT, and 10% 
glycerol) containing 2 μg polydI: dC (Sigma) and 6–20 x 103 cpm of DNA probe at room 
temperature for 20 min. For supershift assays, 0.2 μg rabbit anti-FXR IgG was added and the 
samples were incubated for another 10 min. The binding mixture was then applied onto a 5% 
polyacrylamide gel (0.5 x Tris-Borate-EDTA buffer) for electrophoresis. The gels were dried 
and exposed at –80°C for autoradiography. 
2.2.8 Chromatin Immunoprecipitation (ChIP) Assay 
ChIP assay was performed using a ChIP assay kit (Millipore, Massachusetts, USA) according to 
the instructions of the manufacture. Soluble chromatin was prepared from LX-2 cells treated 
with 1 μM GW4064 for 24 hours. Chromatin was immunoprecipitated with antibodies (2 μg) 
directed against FXR (sc-13063). Final DNA extractions were PCR amplified using primer 
pairs that cover an IR-1 consensus sequence in the miRNA-29a promoter as follows: forward, 
5'-GTGGGTAAGGGAGAGGGAAG-3'; antisense, 5'-ACATTGCCTTCTCCCCAAAG-3'. 
2.2.9 Statistical Analysis 
All data are expressed as means ± standard deviation unless otherwise stated. Comparisons 
between two groups were made with unpaired Student's t-test. Comparisons between three or 
more groups were made with analysis of variance followed by Tukey-Kramer post hoc analysis. 
In all cases, P < 0.05 was considered statistically significant. 
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2.3 RESULTS 
2.3.1 Treatment of rat HSCs with GW4064 led to significant inhibition of the mRNA 
expression of several ECM genes 
Using 6-ECDCA as a specific ligand, Fiorucci and colleagues (Fiorucci et al. 2004) have 
previously shown that activation of FXR leads to a significant inhibition of collagen 1A1 
(COL1A1) expression in both primary rat HSCs and an immortalized human hepatic stellate 
cell line HSC-T6. In this experiment, we examined if GW4064 could similarly inhibit the 
expression of COL1A1 in rat HSCs. GW4064 is also a synthetic ligand that is highly specific 
for FXR and has been widely used in studying FXR-mediated gene regulation in vitro and in 
vivo (Maloney et al. 2000, Li et al. 2009a). Treatment with GW4064 was conducted at the 
concentration of 1 µM for 24 h, which shows optimal sensitivity and specificity based on our 
previous experience. Figure 2 shows that GW4064 treatment resulted in a significant 
downregulation of the expression of COL1A1 mRNA in rat HSCs. GW4064 also significantly 
inhibited the expression of several other fibrosis-related genes including COL1A2, COL3A1, 
COL4A1, COL5A1, elastin 1 (ELN 1), and fibrillin 1 (FBN 1) (Figure 2). Inhibition of ECM 
protein expression by GW4064 was also confirmed as shown in Western analysis of COL1A1 
expression (Figure 3). 
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2.3.2 GW4064 treatment led to upregulation of miR-29a in rat and mouse HSCs 
Following the demonstration of the inhibition of the mRNA expression of several ECM genes 
by GW4064, we went on to explore the potential mechanism involved. We hypothesized that a 
miRNA might be involved based on the fact that a cluster of ECM-related genes were affected 
by GW4064 treatment. Multiple algorithms were used to screen for miRNAs that may be 
involved in the regulation of ECM including Microcosm Targets, TargetScan, and PITA (Lewis 
et al. 2003, Xin et al. 2009, Dong et al. 2010). Members of miR-29 family including miR-29a, 
miR-29b, and miR-29c were identified by all three programs to be the best candidates as ECM-
targeting miRNAs. As an initial step to study a potential role of miR-29a in GW4064-mediated 
effects, we examined if the expression of miR-29a is regulated by GW4064 in HSCs. Figure 4A 
shows that GW4064 treatment resulted in a significant increase in the expression of miR-29a 
gene as assessed by real-time RT-PCR analysis of miR-29a precursor. A similar induction of 
miR-29a expression by GW4064 was also observed in LX-2 cells (an immortalized human 
hepatic stellate cell line) (Figure 4B) and HSCs isolated from wild-type mice (Figure 4C). 
However, no induction of miR-29a was observed in HSCs prepared from FXR-/- mice (Figure 
4D), suggesting that induction of miR-29a by GW4064 was mediated by FXR. 
Interestingly, GW4064 treatment had no effect on the expression of miR-29b in both rat 
and mouse HSCs (Figure 5). Induction of miR-29a in mouse liver was also observed following 
oral delivery of GW4064 (Figure 6). 
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To further establish a role of miR-29a in the regulation of ECM expression we examined the 
effect of miR-29a on the expression of several reporter constructs that contain the respective 3’- 
UTRs from COL1A1, COL3A1 and ELN1 genes. All of the three 3’-UTRs contain a putative 
miR-29a target sequence as analyzed by TargetScan algorithm. As shown in Figure 11A, 
transfection of cells with miR-29a mimic significantly inhibited the expression of the reporter 
construct with an intact COL1A1 3’-UTR. Such inhibitory effect was completely lost for a 
mutant reporter construct lacking the miR-29a target sequence. These results suggest that the 
presence of the miRNA target site in the COL1A1 3'-UTR of the reporter construct is necessary 
for the inhibition by miR-29a. Similar results were observed with the construct with a 3’-UTR 
from either COL3A1 or ELN1 gene (Figure 11B-C). 
2.3.4 Human miR-29a is a likely target gene of FXR 
Upregulation of miR-29a expression by GW4064 suggests that activation of FXR modulates 
miR-29a expression at the transcriptional level. We then hypothesized that activation of FXR 
enhances miR-29a expression via exerting its stimulatory activity on miR-29a promoter. To test 
this hypothesis, we constructed a luciferase reporter expression plasmid (pGL3-miR-29a) that is 
driven by a 1.98 kb sequence of human miR-29a promoter. To examine promoter activation, 
CV-1 cells were co-transfected with pGL3-miR-29a and pCMX-FXR expression vector, 
followed by GW4064 treatment. CV-1 cells instead of HSCs were used for transfection due to 
low transfection efficiency in the HSCs. As shown in Figure 12, treatment with GW4064 
resulted in a significant increase in the transcriptional activity of the miR-29a promoter. To 
further elucidate a role of FXR in regulating miR-29a promoter activity, we then co-transfected 
pGL3-miR-29a with an expression plasmid encoding a constitutively activated FXR, vpFXR. 
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vpFXR was generated by fusing the VP16 activation domain to the N terminus of FXR cDNA 
(Downes et al. 2003). Figure 12 shows that co-expression of vpFXR in CV-1 cells significantly 
enhanced the miR-29a promoter activity, clearly demonstrating that a genetic activation of FXR 
enhances miR-29a promoter activity.  
 
 
Figure 11 miR-29a regulates the expression of ECM genes through targeting at the 3’-UTR of their mRNAs.  
CV-1 cells were transfected with a luciferase construct with Col1A1-3’-UTR (A), Col3A1-3’-UTR (B) or ELN-3’-
UTR (C) in the presence of miR-29a mimic or nonspecific control miRNA mimic. Luciferase assay was performed 
24 h after the transfection. Data shown in the panels represent mean (S.D.) from triplicate assays. n = 3; *, P < 0.05 
(versus control miRNA). 
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further determine whether this IR1 sequence is responsible for FXR-mediated transactivation of 
miR-29a promoter, we generated a mutant pGL3-miR-29a in which this putative FXR binding 
site was eliminated. The wild-type and mutated plasmids were then similarly transfected into 
the CV-1 cells, and their transfection efficiency was compared. Figure 13C shows that the FXR-
mediated activation of miR-29a promoter was substantially diminished when the miR-29a/IR1 
site was eliminated. The above studies strongly suggested a likely role of miR-29a/IR1 element 
in FXR-mediated transactivation of human miR-29a promoter.  
Figure 13D shows the result of an EMSA with a 20 bp oligonucleotide that contains the 
putative FXRE (lanes 1 ~ 5). A typical IR1/FXRE oligonucleotide was also included as a 
positive control (lanes 6 ~ 10) because FXR is known to bind to IR1 with high specificity and 
affinity. Interaction of the oligonucleotide with in vitro translated FXR/RXR yielded a 
DNA/protein band of expected mobility (lane 1). This binding was specific, as it was inhibited 
by addition of excess unlabelled (cold) miR-29a/IR1 (lane 2) or IR1/FXRE (lane 4) but not a 
mutated miR-29a/IR1 (lane 3). Addition of antibody against FXR to the reaction mixture 
resulted in the disappearance of the radiolabeled band (lane 5) (Figure 13D). This supershifting 
confirms the identity of the protein that interacts with the DNA as being FXR. 
To further demonstrate the binding of FXR to miR-29a/IR1, chromatin 
immunoprecipitation (ChIP) assay was then performed. In this experiment, LX-2 cells were 
treated with vehicle (DMSO) or GW4064 for 24 h before ChIP analysis using an anti-FXR 
antibody or the control mouse IgG. As shown in Figure 13E, treatment of LX-2 cells with 
GW4064 led to a significant increase in the recruitment of FXR to miR-29a/IR1. Together these 
results suggested that miR- 29a is a direct transcriptional target of FXR. 
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2.4 DISCUSSION 
We have demonstrated in this study that miR-29a was significantly upregulated in HSCs 
following treatment with GW4064, a synthetic FXR-specific agonist. Overexpression of miR- 
29a in HSCs resulted in a significant inhibition of the mRNA expression of a number of ECM 
genes including collagens, elastin and fibrillin. MiR-29a also significantly inhibited the 
expression of a reporter expression plasmid that contains a full-length 3'-UTR from COL1A1, 
COL3A1 or ELN1 gene. These results are consistent with the notion that miR-29a may be 
critically involved in the FXR-mediated inhibition of ECM expression in HSCs. 
Induction of miR-29a in HSCs is likely to be mediated by FXR as: a) GW4064 is highly 
specific for FXR and is often used as a "chemical tool" to show that BA target genes are 
regulated in a FXR-specific manner (Maloney et al. 2000); and b) the induction of miR-29a was 
abolished in FXR-/- mouse HSCs. We have also identified an imperfect IR1 as a FXRE that 
appears to be involved in GW4064-mediated upregulation of miR-29a in HSCs. IR1 is a typical 
FXRE that has been implicated in the regulation of a number of FXR target genes. Thus, miR-
29a is a likely target gene of FXR. 
Various biological functions have been reported for members of miR-29 family 
including miR-29a, b and c. These include modulations of self-renewal in hematopoietic 
progenitor cells (Han et al. 2010), regulations of WNT signaling in human osteoblasts (Kapinas 
et al. 2010), control of host-HIV-1 interactions (Nathans et al. 2009), and regulation of the 
expression of ECM in fibroblasts and stellate cells (Jiang et al. 2010) etc. Clearly, the biological 
functions of miRNAs are complex and may be tissue- or cell type-specific. A study from van 
Rooij et al. (van Rooij et al. 2008) has shown that dysregulation of miR-29 plays an important 
role in cardiac fibrosis following myocardial infarction. All three members of miR-29 family 
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were downregulated in the region of heart adjacent to the infarct. Systemic delivery of a 
cholesterol-conjugated miR-29b inhibitor led to increased expression of collagen in liver, 
kidney and heart, suggesting a role of miR-29 in regulating the expression of ECM in vivo (van 
Rooij et al. 2008). Recently, downregulation of miR-29 has also been shown in rodent models 
of liver fibrosis and in liver biopsies from patients with HCV infection (Kwiecinski et al. 2009, 
Pogribny et al. 2010). The role of miR-29 members in liver fibrosis was further demonstrated in 
a recent study by Roderburg et al. in which all members of miR-29 were significantly 
downregulated in mouse liver in both CCl4 and common bile ligation models (Roderburg et al. 
2011). They have further shown that TGF-β or NF-κB signaling negatively regulated the 
expression of miR-29, suggesting TGF-β↑→miR−29↓ or NF-κB↑→miR-29↓ as an important 
mechanism in the development of liver fibrosis (Roderburg et al. 2011). A similar role of TGF-
β↑→miR−29↓ was also demonstrated in a mouse model of lung fibrosis (Cushing et al. 2011). 
These data, together with our observation that activation of FXR led to upregulation of miR-
29a, strongly support an important role of miR-29 in the control of ECM expression under both 
physiological and pathophysiological conditions. They also suggest the potential of miR-29 as a 
novel therapeutics for the treatment of various fibrotic diseases including liver fibrosis. 
It is likely that other mechanisms are involved in the antifibrotic effect of FXR/FXR 
ligands in addition to a direct activation of the miR-29a gene. A number of studies including our 
work have suggested that many nuclear receptors such as FXR and SHP inhibit various 
inflammatory signalings including NF-κB, AP-1, and TGF-β via competition for essential 
cofactors or recruitment of corepressors (He et al. 2006, Zhang et al. 2011b). Therefore, it is 
possible that treatment of HSCs with FXR ligands at quiescent stage may prevent the NF-κB- 
and/or TGF-β-mediated downregulation of miR-29 expression during their transactivation 
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process. Studies are currently ongoing in our laboratory to test this hypothesis. Alternatively, 
FXR and/or SHP may directly inhibit the expression of fibrosis-related genes through the 
interference of AP-1 and/or TGF-β signaling as suggested by Fiorucci et al. in their study 
(Fiorucci et al. 2004). Clearly, more studies are required in the future to better understand the 
contribution of each potential mechanism to the overall antifibrotic effect of FXR. 
Animal models are indispensable in simulating the micro-environment composed of 
various cell types in the fibrotic liver. Two of the most commonly used models of experimental 
fibrosis are bile duct ligation (BDL) and iterative toxic damage (for example, elicited by CCl4 
intoxication). BDL results in a reproducible portal tract fibrosis over a short period of time (4-6 
weeks in rats, 2-3 weeks in mice). However, it shows little resemblance to human fibrotic liver 
diseases (except for chronic biliary obstruction) and an altered metabolism of most drugs that 
are primarily secreted through the biliary tract or that undergo enterohepatic circulation. Liver 
fibrosis induced by carbon tetrachloride (CCl4) results from repetitive (necrotic) hepatocyte 
death. It allows the study of acute liver injury, advanced fibrosis, and fibrosis reversal. The 
major disadvantages are the severe hepatocyte necrosis and its dependence on massive oxidative 
stress that is not found to such an extent in human chronic liver diseases (Popov et al. 2009). In 
addition, tissue bank serves as a tissue procurement resource which provides ethically-collected, 
highly-annotated tissue specimens for academic research. Liver specimens at difference fibrotic 
stages could be a useful resource to provide data that are more clinically relevant. 
It should be noted that, despite a similar function in regulation of ECM expression, miR-
29a, b and c may be differentially up- or down-regulated under different physiological or 
pathophysiological conditions. MiRNA-29a and miR-29b1 are clustered together and are 
located in chromosome 7 in humans, whereas the miR-29b2/miR-29c cluster is found on 
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chromosome 1. A study by (Pogribny et al. 2010) shows that miR-29c was downregulated in a 
mouse model of dietary nonalcoholic steatohepatitis. In contrast, in a rat model of common bile 
duct ligation and in liver biopsies from HCV patients, prominent downregulation of miR-29a 
and moderate downregulation of miR-29b were observed (Kwiecinski et al. 2009). We only 
observed a significant upregulation of miR-29a in both mouse and rat HSCs following GW4064 
treatment, which is likely due to lack of functional FXR response element in the miR-
29b2/miR-29c transcriptional unit. This is in contrast to downregulation of all members of miR-
29 family in mouse models of liver fibrosis in the study by Roderburg et al., which may be due 
to the fact that the expression of both miRNA-29a/miR-29b1 and miR-29b2/miR-29c is 
negatively regulated by NF-κB and/or TGF-β signaling. This may reflect a complex mechanism 
in the regulation of miRNA expression. 
In summary, we have shown for the first time that activation of FXR led to expression of 
miR-29a in HSCs, which may play an important role in FXR-mediated antifibrotic effect. Our 
study provides new insight into the mechanism by which FXR/FXR ligands control the 
expression of ECM in HSCs. It also suggests a miR-29a-based new therapy for the treatment of 
liver fibrosis. 
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3.0  MIR-29B INHIBITS COLLAGEN MATURATION IN HEPATIC STELLATE 
CELLS THROUGH DOWN-REGULATING THE EXPRESSION OF HSP47 AND 
LYSYL OXIDASE 
3.1 BACKGROUND 
Liver fibrosis is a wound-healing response characterized by an increased and altered deposition 
of extracellular matrix (ECM) components, particularly collagen type I and III (Olaso et al. 
1998). In progressive fibrosis, the ECM accumulates gradually and disrupts the function of 
normal tissues, leading to liver dysfunction and ultimately end-stage organ failure. It has been 
demonstrated that liver fibrosis can be inhibited by suppressing the synthesis of ECM such as 
collagen.  
The biosynthesis of collagen is a multi-step process. The regulation of this process 
involves many intracellular and extracellular factors such as HSP47 and LOX. HSP47 is an 
endoplasmic reticulum (ER)-resident molecular chaperone specific for collagen synthesis, and it 
plays an essential role in procollagen processing. After the synthesis of α-polypeptide chains, 
HSP47 assists in the correct folding and stabilization of triple-helical procollagen molecules 
(Nagata 1996). This process is crucial for subsequent secretion, cleavage and fibril formation of 
collagen (Ishida et al. 2006). The role of HSP47 on collagen maturation has been demonstrated 
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both in vitro and in vivo (Hosokawa et al. 1998, Nagai et al. 2000, Rocnik et al. 2002, Ishida et 
al. 2006).  
Lysyl oxidase (LOX) is an extracellular enzyme that catalyzes the oxidative deamination 
of hydroxylysine and lysine residues in collagen and elastin. The resulting peptidyl aldehyde 
products spontaneously form covalent cross-links with unmodified lysine residues or with other 
peptidyl aldehyde residues. These cross-links are necessary for the formation of insoluble 
collagen and elastic fibers as well as mature functional extracellular matrix (Kagan et al. 1991). 
Abnormally increased lysyl oxidase enzyme activity can lead to excessive accumulation of 
insoluble collagen fibers and is directly associated with fibrotic diseases (Sommer et al. 1993, 
Kagan 2000). 
MiRNAs are small non-coding RNAs that play a central role in gene regulation (He et 
al. 2004). MiRNAs repress the expression of target genes by interacting with their 3'-UTRs, 
causing mRNA degradation or translational repression. Accumulating data have demonstrated 
the critical role of miRNAs in fibrotic diseases. For example, miR-27a and 27b were shown to 
reverse the transactivation and inhibit the proliferation of HSCs by targeting the retinoid X 
receptor α . It was also shown that miR-15b and miR-16 can promote apoptosis by targeting 
Bcl-2 and the caspase signaling pathway (Guo et al. 2009). Lakner et al. showed that the 
expression of miR-19 was significantly down-regulated in activated HSCs (Lakner et al. 2012). 
Transfection of activated HSCs with miR-19b mimic negatively regulated TGF-β signaling 
components, as demonstrated by decreased TGF-β receptor II (TGF-βR II) and SMAD3 
expression (Lakner et al. 2012). Among the reported miRNA species that were involved in liver 
fibrosis, miR-29 is emerging as a key suppressor of fibrotic changes (van Rooij et al. 2008, 
Roderburg et al. 2011). MiR-29 is significantly down-regulated during liver fibrosis in mice and 
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humans (Roderburg et al. 2011), and extensive interest has been focused on the mechanism by 
which miR-29b inhibits fibrosis. For example, Kwiecinski et al. have identified the 
profibrogenic growth factors PDGF-B, PDGF-C, IGF-I and VEGF-A as target genes of miR-29 
(Kwiecinski et al. 2010). We and others recently showed that members of miR-29 family can 
down-regulate multiple genes coding for ECM proteins including collagens, fibrillins, and 
elastin (Luna et al. 2009, Li et al. 2011a, Sekiya et al. 2011). This regulation is achieved at post-
transcriptional or translational level by targeting to their 3'-UTR. 
In addition to altering the ECM expression at mRNA or translational level, microRNAs 
can also regulate the post-translational maturation of ECM by targeting relevant genes. For 
example, we have recently shown that miR-122 expression was significantly reduced in 
transactivated HSCs and in the livers of mice treated with CCl4 (Li et al. 2013a). In addition, 
over-expression of miR-122 markedly attenuated the expression of prolyl 4-hydroxylase subunit 
alpha-1 (P4HA1), leading to decreased collagen maturation and ECM production (Li et al. 
2012). However, a possible role of miR-29b in post-translational modifications of ECM remains 
unexplored. The purpose of this study was to determine whether miR-29b plays a role in ECM 
maturation through a post-translational mechanism. Our data showed that miR-29b was down-
regulated during liver fibrosis and stellate cell activation, which was associated with an up-
regulation of HSP47 and LOX expression. In contrast, a forced expression of miR-29b in 
cultured hepatic stellate cells inhibited the expression of HSP47 and LOX and led to defective 
regulation of ECM maturation. Our findings suggest that miR-29b is involved in the regulation 
of ECM maturation by targeting HSP47 and LOX. 
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3.2 METHODS 
3.2.1 Ethics Statement 
All procedures in the animals and cell culture studies were reviewed and approved by 
Institutional Animal Care and Use Committee of the University of Pittsburgh. The animals were 
housed and maintained in compliance with standards established in the Animal Welfare Act and 
the Guide for the Care and Use of Laboratory Animals (IACUC#: 1103914). 
3.2.2 Animals and cell culture 
Primary rat HSCs were isolated from retired male Sprague-Dawley rats (Charles River 
Laboratories. Wilmington, MA) (Thirunavukkarasu et al. 2005). HSCs were used 3 days after 
isolation as quiescent cells, and 7-14 days after isolation as activated cells. The purity of our 
primary rat HSCs was >95% (Thirunavukkarasu et al. 2005). The immortalized human hepatic 
stellate cell line LX-2 was kindly provided by Dr. Scott L. Friedman (Mount Sinai School of 
Medicine, New York, NY, USA) (Xu et al. 2005). Unless otherwise stated, all of the cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 mg/mL glucose, 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 g/mL streptomycin at 
37°C in 5% CO2. All products for cell culture were purchased from Invitrogen (Carlsbad, CA). 
To establish an animal model of liver fibrosis, carbon tetrachloride (CCl4; Merck; 0.6 mL/kg of 
body weight) was injected to CD-1 mice (Charles River Laboratories, Wilmington, MA) 
intraperitoneally twice a week for six weeks (Li et al. 2012). Common bile duct ligation 
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(CBDL) was performed on rats according to the literature (Roderburg et al. 2011). Sham-
operated rats served as controls. HSCs were isolated 3 weeks following CBDL. 
3.2.3 RNA isolation and qRT-PCR 
Total RNA was extracted from cells and tissues with TRIzol reagent, and the first-strand cDNA 
was synthesized using SuperScript III reverse transcriptase according to manufacturer's 
instructions (Invitrogen, San Diego, CA). The qRT-PCR was performed using SYBR Green-
based assays with the ABI Prism 7300 Real-Time PCR System (Applied Biosystems, Foster 
City, CA) (Li et al. 2011a). The analysis of miR-29b expression was performed according to our 
previous protocol (Li et al. 2012). Briefly, total RNA enriched with miRNAs was isolated from 
HSCs using the mirVana miRNA isolation kit (Applied Biosystems. Foster City, CA), followed 
by stem-loop real-time RT-PCR (SLqRT-PCR). The primers for qRT-PCR were obtained from 
MWG Biotech, and their sequences are listed in Appendix A.The relative transcript abundance 
was analyzed as previously reported (Li et al. 2011a) and calculated from three independent 
experiments. 
3.2.4 Western Blot Analysis 
Forty-eight h after transfection with 50 nM of control miRNA or miR-29b, the whole-cell 
lysates of LX-2 cells were prepared as described previously (Li et al. 2011a). Equal amounts of 
protein (30 µg) were separated by 10% SDS-polyacrylamide gel and transferred to PVDF 
membrane (Millipore, Billerica, MA). The membranes were blocked in phosphate-buffered 
saline with 0.05% Tween 20 (TPBS) containing 5% skim milk and incubated with specific 
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primary antibody (rabbit anti-HSP47 IgG, rabbit anti- β-actin IgG or goat-anti-LOX IgG, Santa 
Cruz Biotechnology) overnight, followed by incubation with secondary antibody (horseradish 
peroxidase-conjugated goat anti-rabbit IgG or horseradish peroxidase-conjugated donkey anti-
goat IgG, Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h. ECL 
chemiluminescence kit (Amersham Biosciences, Piscataway, NJ) was used to detect the signals 
from HSP47 and β-actin, and the LOX signal was detected with the SuperSignal West Femto 
Chemiluminescent Substrate (Thermo Fisher Scientific).. 
3.2.5 Plasmid Constructs 
The wild-type 3'-UTR of HSP47 and LOX genes were PCR amplified from human genomic 
DNA using the primers listed in Appendix A. The mutant 3'-UTR of HSP47 without putative 
miR-29b-binding sequence was also amplified. To clone the mutant 3'-UTR of LOX without the 
putative miR-29b binding sites, two fragments of LOX 3'-UTR were amplified separately and 
joined by overlap extension PCR according to a published method (Ho et al. 1989). The PCR 
products of wild-type or mutant 3'-UTR for HSP47 were then cloned into the MluI-HindIII site 
downstream of the stop codon in the pMIR-REPORT Firefly Luciferase reporter vector 
(Ambion). The segments of wild-type or mutant 3'-UTR for LOX were cloned into the same 
vector at SacI-MluI site. The sequences of the generated constructs were confirmed by 
restriction digestion and sequencing. 
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3.2.6 Transfection and luciferase assays 
LX-2 cells were grown in 96-well plates. Reporter plasmids and miRNAs (ABI, Applied 
Biosystems, Foster City, CA) were co-transfected into LX-2 cells using Lipofectamine2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instruction. To normalize the value 
of luciferase activity for transfection efficiency and cell viability after transfection, the pCMV-
βgal plasmid was co-transfected (Umesono et al. 1991). Cells were washed and lysed 24h 
following transfection as described (He et al. 2006), and the luciferase activity and β-
galactosidase activity were measured. Transfection experiments were repeated three times 
independently and in each case were done in triplicate. Data were presented as relative 
luciferase activity of control miRNA. 
3.2.7 Electron Microscopy 
For the TEM study, LX-2 cells were cultured in 10% fetal bovine serum /DMEM in the 
presence of ascorbic acid phosphate (136 µg/mL). The EM study was performed 3-5 days after 
the cell culture became confluent. Cultured cells were rinsed in PBS and fixed with cold 2.5% 
glutaraldehyde in 0.1 M PBS. The specimens were rinsed in PBS, post-fixed in 1% Osmium 
Tetroxide with 0.1% potassium ferricyanide, rinsed in PBS, dehydrated through a graded series 
of ethanol and embedded in Epon.  Semi-thin (300 nm) sections were cut on a Reichart Ultracut, 
stained with 0.5% Toluidine Blue and examined under the light microscope.  Ultrathin sections 
(65 nm) were stained with uranyl acetate and Reynold’s lead citrate and examined on Jeol 1011 
transmission electron microscope. 
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3.2.8 LOX Activity Assays 
To measure the effect of miR-29b on extracellular LOX activity, LX-2 cells were transfected 
with control miRNA or miR-29b and cultured in complete medium until confluent at which 
time it was replaced by serum free, phenol red free DMEM. At 3 days post-confluence, the 
conditioned media were collected and concentrated using 10,000 molecular weight cut-off 
Amicon Ultra centrifugal filter units (Millipore) (Fogelgren et al. 2005). The LOX enzyme 
activity of concentrated media was measured using the Amplex Red fluorescence assay as 
previously described (Palamakumbura et al. 2002). Briefly, the samples were incubated with the 
reaction mixture at 37 °C for 1 h, which consisted of 50 mM sodium borate (pH 8.2), 1.2 M 
urea, 50 µM Amplex Red (Sigma-Aldrich), 0.1 units/mL horseradish peroxidase, and 10 mM 
1,5-diaminopentane (cadaverine) substrate in the presence or absence of 500 µM β-
Aminopropionitrile (BAPN, Acros Organics). After incubation, the fluorescence intensity of 
each sample was determined by a PerkinElmer LS 50B luminescence spectrometer (Waltham, 
MA) (λex = 560 nm; λem = 590 nm). The difference of fluorescent intensity value between the 
samples with or without BAPN was used to calculate the specific LOX activity. Data was 
normalized by total protein amount and expressed as the fold induction over control samples. 
All samples were assayed in triplicate. 
3.2.9 Statistical Analysis 
Unpaired Student’s t-test was performed on data of qRT-PCR and luciferase assays. All data are 
reported as means ± standard deviations unless otherwise stated. P < 0.05 was considered 
statistically significant. 
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3.3 RESULTS 
3.3.1 Expression level of HSP47 and LOX are upregulated in cellular and animal models 
of liver fibrosis, with down-regulation of miR-29b 
We hypothesized that miR-29b is involved in the post-translational modification of ECM 
proteins in addition to its role in regulating ECM expression at mRNA and translational levels. 
Computational prediction by the algorithms Target scan and miRanda has identified HSP47 and 
LOX as potential target genes of miR-29. Therefore, we further hypothesized that miR-29b 
inhibits ECM maturation through targeting HSP47 and LOX. To test this hypothesis, we first 
examined the expression level of HSP47, LOX and miR-29b in the CCl4-induced model of liver 
fibrosis. I.P. injection of CCl4 to mice for 6 weeks resulted in significant upregulation of HSP47 
and LOX mRNA in liver tissue (Figure 14A-B). Similarly, the protein expression of HSP47 and 
LOX in the liver of CCl4 treated mice was significantly increased compared with vehicle-treated 
group (Figure 14C). This is consistent with the reported data that the expression of HSP47 
(Masuda et al. 1994) and LOX (Furui et al. 1995) was markedly induced during the progression 
of CCl4-induced liver fibrosis in rats. The expression of miR-29b in mice liver tissue was 
measured by SLqRT-PCR technique. The results showed that there was a significant decrease in 
the expression of miR-29b in the fibrotic liver (Figure 14D). 
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Figure 14 Altered expression of HSP47, LOX and miR-29b in mouse liver following CCl4 treatment.  
CD-1 mice were treated with corn oil or CCl4 for 6 weeks as described in the Materials and methods. Liver tissues 
were harvested and Quantitative PCR was conducted to detect the mRNA expression levels of HSP47 (A) and 
LOX (B). (C) Western blots were conducted to detect the protein expression levels of HSP47 and LOX. (D) 
Expression of miR-29b was decreased in the liver of mice treated with CCl4. *P < 0.05, **P < 0.01. 
 
Since HSCs are the major source of ECM and become activated during liver fibrosis, we 
have also examined the gene expression in primary-cultured rat HSCs. Data showed that the 
expression of HSP47 and LOX in culture-activated HSCs was dramatically increased at both 
mRNA (Figure 15A-B) and protein levels (Figure 15C) compared with that in quiescent cells. 
The over-expression of HSP47 and LOX in activated HSCs was accompanied by the reduced 
expression of miR-29b (Figure 15D). In an independent model of liver fibrosis induced by bile 
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duct ligation, the in vivo activated HSCs isolated from bile duct ligated rats showed higher level 
of HSP47 and LOX expression than HSCs from normal rats (Figure 15E-F). 
 
Figure 15 Altered expression of HSP47, LOX and miR-29b in rat HSCs during culture-induced activation.  
Quiescent and activated HSCs of rat were isolated and harvested as described in the Materials and methods. 
Quantitative PCR was conducted to detect the mRNA expression levels of HSP47 (A) and LOX (B). (C) Western 
blots were conducted to detect the protein expression levels of HSP47 and LOX. (D) Expression of miR-29b was 
decreased in the activated HSCs. Expression of HSP47 (E) and LOX (F) mRNA in HSCs was up-regulated at 3 
weeks following CBDL-induced liver fibrosis of rats.*P < 0.05, **P < 0.01. 
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3.3.2 Transfection of LX-2 cells with miR-29b led to a significant inhibition of HSP47 
and LOX expression 
LX-2 is an immortalized human hepatic stellate cell line that exhibits typical features of 
primary HSCs such as over-expression of α-SMA and responsiveness to transforming growth 
factor-β (TGF-β) (Xu et al. 2005). TGF-β signaling is known to play an important role in 
stimulating stellate cell activation and ECM synthesis (Gressner et al. 1993, Gressner 1995). To 
define a role of TGF-β signaling in regulating the expression of HSP47, LOX, and miR-29b 
during HSC transactivation, the mRNA expression levels of these genes were examined in LX-2 
cells with or without TGF-β1 treatment. Figure 16A-B showed that the expression of Col1A1 
and Col3A1 was significantly up-regulated following TGF-β treatment, which was consistent 
with the known effect of TGF-β on collagen expression (Li et al. 2012). TGF-β-treatment also 
led to significant increases in the mRNA expression levels of HSP47 and LOX in LX-2 cells 
(Figure 16C-D). Again, these changes were associated with a decrease in the expression level of 
miR-29b (Figure 16E). These results strongly suggest a role of TGF-β signaling in regulating 
the expression of HSP47, LOX, and miR-29b during HSC transactivation. 
3.3.3 miR-29b down-regulated gene expression by targeting the putative binding 
sequence on the 3’-UTRs of HSP47 and LOX 
The above studies clearly show an inverse correlation between miR-29b and 
HSP47/LOX gene expression in both fibrotic liver and transactivated HSCs. To evaluate the 
contribution of decreased miR-29b expression to the increased expression of HSP47 and LOX  
 66 
 
Figure 16 TGF-β treatment induced HSP47 and LOX mRNA expression and suppressed miR-29b 
expression in LX-2 cells.  
LX-2 cells were treated with TGF-β (5ng/ml) as described in the Materials and methods and harvested at 24h after 
treatment. Quantitative PCR was conducted to detect the mRNA expression levels of Col1A1 (A), Col 3A1 (B), 
HSP47 (C) and LOX (D). (E) Expression of miR-29b was decreased in the activated HSCs. *P < 0.05. 
 
during fibrotic changes, we investigated the effect of forced expression of miR-29b on the 
HSP47 and LOX expression level in LX-2 cells. LX-2 cells were transfected with miR-29b or 
control sequence and the mRNA expression of HSP47 and LOX was examined 24 h later by 
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real-time RT-PCR. The data showed that transfection of LX-2 cells with miR-29b led to a 
significant inhibition of HSP47 and LOX expression at both mRNA (Figure 17A-B) and protein 
(Figure 17C) levels. 
 
Figure 17 Transfected miR-29b decreased the expression of HSP47 and LOX and mRNA and protein levels.  
Cells were transfected with either non-specific control miRNA or miR-29b at a final concentration of 50 nM. The 
mRNA expression levels of HSP47 (A) and LOX (B) were analyzed by qRT-PCR at 24 h post-transfection. Data 
represent quantification of four independent experiments, *p < 0.05 (vs. control miRNA). (C) Western blots were 
conducted to detect the HSP47 and LOX expression at 48 h post-transfection. 
 
To confirm whether HSP47 and LOX are direct targets of miR-29b, the 3'-UTR of 
HSP47 or LOX gene containing the putative target sites (wild-type HSP47 3'-UTR and wild-
type LOX 3'-UTR, Figure 18A) was subcloned into a luciferase reporter vector. A control 
reporter plasmid was similarly constructed in which the putative target sites were deleted 
(mutant HSP47 3'-UTR and mutant LOX 3'-UTR, Figure 18A). Each plasmid construct was co-
transfected with miR-29b or control miRNA into LX-2 cells, followed by measurement of  
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Figure 18 MiR-29b directly targets the 3'-UTR of HSP47 and LOX mRNAs.  
(A) Scheme of wild-type and mutant 3'-UTRs of human HSP47 and LOX. Wild type 3’-UTRs include the putative 
binding sites highlighted. Deletion mutant eliminates the putative binding sites. (B) LX-2 cells were transfected 
with a luciferase construct with HSP47-3'-UTR in the presence of 50 nM miR-29b or non-specific control miRNA. 
Luciferase assay was performed 24 h post-transfection. Transient transfection of miR-29b in LX-2 cells decreased 
the luciferase activity of the wild-type HSP47-3'-UTR construct, whereas no change in the luciferase activity of 
mutant HSP47-3'-UTR construct was seen. (C) Same experiment with LOX 3'-UTR luciferase vectors as in (B), 
miR concentration=10nM. Luciferase activity was normalized against the control groups. Data shown in the panels 
represent means± (SD) of the fold increase over the control. N = 3. *P < 0.05 (vs. control miRNA). 
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luciferase activity. As shown in Figure 18B, miR-29b significantly inhibited the luciferase 
activity of the wild-type HSP47-3'-UTR construct. In contrast, such an inhibitory effect was 
essentially abolished when the putative miR-29b target sequence is deleted from the reporter 
construct (Figure 18B). Similar results were observed with the plasmid construct containing the 
3'-UTR of LOX gene (Figure 18C). These data suggest that miR-29b down-regulated the 
expression of HSP47 and LOX via targeting the putative binding sequence on the respective 3'-
UTR of HSP47 and LOX mRNA. Taken together, all of the data above suggest a causal effect 
of decreased miR-29b expression on the upregulation of HSP47 and LOX during fibrotic 
changes. 
3.3.4 The functions of HSP47 and LOX in LX-2 cells were inhibited by transfection with 
miR-29b 
To investigate the physiological significance of the inhibitory effect of miR-29b on LOX 
expression, we transfected LX-2 cells with miR-29b and examined its effect on LOX enzymatic 
activity. Since LOX is a secreted enzyme, the conditioned medium was collected after 
transfection to determine the enzyme activity of LOX in extracellular environment. Figure 19A 
shows that LOX activity was significantly decreased by miR-29b compared with control 
miRNA. As a positive control, the known LOX inhibitor BAPN also showed inhibition on LOX 
activity (Figure 19B). 
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Figure 19 Extracellular LOX activity of LX-2 cells transfected with miR-29b.  
(A) Extracellular LOX enzyme activity was significantly reduced in the 72 h supernatant of miR-29b transfected 
LX-2 cells than that of control miRNA transfected cells. (B) LOX activity in the conditioned media was 
significantly inhibited by 100µM BAPN.  Data represent mean ± SD, n = 3. *P < 0.05. 
 
After demonstrating the inhibitory effect of miR-29b on HSP47 and LOX expression, we 
further investigated the role of miR-29b in the post-translational maturation of ECM. LX-2 cells 
were transfected with miR-29b and the morphology of extracellular fibrils was examined by 
electron microscopy. The extracellular fibrils from control miRNA treated cells were organized 
as expected (Figure 20A-C). This is in contrast with those from miR-29b transfected cells, 
which were relatively thin and sparse, and frequently contained more branches (Figure 20D-F). 
This difference became more dramatic at day 5 post-confluence compared to day 3 and day 4. 
These observations are consistent with the reported data generated from HSP47-/- embryonic 
fibroblasts (Ishida et al, 2006) or BAPN-treated osteoblasts (Hong et al, 2004). These results 
suggest that miR-29b over-expression can lead to defects of extracellular fibrils, with the 
potential contribution from HSP47 and LOX inhibition. 
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Figure 20 Effect of miR-29b on the morphology of extracellular fibrils secreted from LX-2 cells.  
LX-2 cells were transfected with control miRNA (A-C) or miR-29b (D-F). The extracellular fibrils were observed 
by Transmission Electron Microscopy at 3 d (A and D), 4 d (B and E) and 5 d (C and F) after the cells became 
confluent. Bar, 100 nm. 
 
 
Figure 21 Dilation of the ER following miR-29b tranfection examined by transmission electron microscopy.  
LX-2 cells were transfected with control miRNA (A-C) or miR-29b (D-F) and samples were harvested at 3 d (A 
and D), 4 d (B and E) and 5 d (C and F) post-confluence. Arrows indicate the ER. Bar, 1 µm. 
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Besides the change of ECM morphology, we also noticed dramatic ER dilation in miR-
29b-treated LX-2 cells compared with control miRNA-treated cells (Figure 21A-F), and this 
difference was most dramatic at day 5 post-confluence (Figure 21C and 21F). This observation 
is in agreement with the notion that miR-29b can decrease HSP47 expression, leading to the 
accumulation of misfolded collagen in the ER lumen. 
3.4 DISCUSSION 
Various miRNAs have been reported to regulate the synthesis of ECM proteins. We and 
others have previously demonstrated that miR-29 significantly down-regulates expression of 
several ECM genes including collagen (Li et al. 2011a, Sekiya et al. 2011), fibronectin (Sekiya 
et al. 2011) and lamininγ1 (Sengupta et al. 2008). In addition, it has been reported that miR-17 
(Shan et al. 2009) and miR-199 (Lee et al. 2009) down-regulate fibronectin expression. In 
addition, Col 1A2 and laminin γ1 have been validated as direct targets of let-7g (Ji et al. 2010) 
and miR-124 (Cao et al. 2007), respectively. In this study we reported a novel mechanism by 
which miR-29b inhibits the ECM synthesis at post-translational level. Specifically, we showed 
that miR-29b inhibited the post-translational maturation of ECM by targeting HSP47 and LOX. 
Through bioinformatic analysis by Targetscan and miRanda, we identified putative miR-
29b binding sites on the 3'-UTR of two genes, HSP47 and LOX, which are critically involved in 
the post-translational modification of ECM. Our data showed that both mRNA and protein 
expression of HSP47 and LOX in liver tissue was highly up-regulated in CCl4-induced fibrosis, 
and their expression level in rat HSCs was also increased during cell transactivation in vitro and 
in vivo. The up-regulation of HSP47 and LOX was consistently associated with a dramatic 
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down-regulation of miR-29b expression in all studies, which strongly supports a correlation 
between miR-29b and those two genes. This inverse correlation was further confirmed in TGF-β 
treated LX-2 cells. Transfection of LX-2 cells with miR-29b led to reduced expression of 
HSP47 and LOX at both mRNA and protein levels. In addition, the predicted miR-29b targeting 
sites at the 3'-UTR of HSP47 and LOX were validated by luciferase reporter assay, indicating 
that HSP47 and LOX are direct targets of miR-29b. Furthermore, over-expression of miR-29b 
in LX-2 cells can lead to abnormal morphology of ECM fibrils according to TEM images, 
suggesting a significant role of miR-29b in post-translational maturation of ECM. Taken 
together, our data strongly support the role of miR-29b in inhibiting the ECM maturation via 
targeting HSP47 and LOX. 
In view of the critical role of HSP47 and LOX in stabilizing collagen fibrils, both have 
been investigated as molecular targets in developing new therapies for the treatment of fibrotic 
diseases including liver fibrosis. HSP47 is a collagen-specific chaperone that is essential for the 
maturation of collagen, which is the dominant ECM constituent in the fibrotic tissue (Guo et al. 
2004).  The absence of HSP47 in collagen-producing cells can lead to several consequences. 
Firstly, HSP47 knockout can cause deficiency of collagen maturation and increase the 
susceptibility of collagen triple helices to protease digestion (Ishida et al. 2006). Secondly, 
HSP47-/- cells showed significantly reduced collagen secretion rate and highly accumulation of 
insoluble aggregate of collagen in the ER, which induced ER stress and apoptosis of collagen-
producing cells through the up-regulation of CHOP (Marutani et al. 2004). Both accelerated 
collagen degradation and induction of apoptosis of ECM-producing cells help to inhibit the 
ECM accumulation. Thus, HSP47 inhibitors have been explored for the treatment of fibrotic 
diseases. Pirfenidone, a small-molecule drug with well-established anti-fibrotic efficacy, 
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significantly inhibited the TGF-β1-stimulated expression of HSP47 in lung fibroblasts 
(Nakayama et al. 2008) and A549 cells (Hisatomi et al. 2012). In addition, suppression of 
HSP47 by specific siRNA significantly reduced the accumulation of collagens and delayed the 
progression of fibrotic diseases in experimental animal models (Wang et al. 2008b, Xia et al. 
2008). Another study has shown that vitamin A-modified liposomal formulation carrying 
siRNA against mRNA encoding rat gp46, a homolog of HSP47, decreased collagen deposition 
in fibrotic rat liver (Sato et al. 2008). Likewise, miR-29b-mediated down-regulation of HSP47 
likely contributed to the production of sparse and branched extracellular fibrils by miR-29b-
transfected cells (Figure 20D-F). We have further shown a dramatic dilation of the ER in miR-
29b-treated LX-2 cells (Figure 21D-F), which is probably caused by accumulation of misfolded 
collagen aggregates in the ER. The dilation of ER in miR-29b over-expressing cells provides 
another functional evidence for the down-regulation of HSP47 by miR-29b in LX-2 cells. 
The lysyl oxidase family consists of five members: lysyl oxidase (LOX) and lysyl 
oxidase-like 1–4 (LOXL1-LOXL4). All members share conserved C-terminal catalytic domains 
that contribute to the enzyme activity in catalyzing the cross-linking of collagen and elastin 
molecules (Kagan et al. 2011). The protein expression and activity LOX and LOXL were shown 
to be up-regulated in various fibrotic diseases including liver fibrosis (Siegel et al. 1978, Kim et 
al. 1999) and atrial fibrillation (Adam et al. 2011). β-Aminopropionitrile (BAPN) is a potent 
irreversible inhibitor of LOX that specifically inhibits all LOX isoenzymes except LOXL2 
(Payne et al. 2007). BAPN has been studied for its antifibrotic efficacy in animal models of 
liver fibrosis (Kagan 2000) and lung fibrosis (Riley et al. 1982). Treatment of rats with BAPN 
inhibited the early increases in liver stiffness, which is important for initiating the early stages 
of fibrosis (Georges et al. 2007). There was also a significant decrease in the α-SMA positive 
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area in the liver section of CCl4/BAPN treated rats compared with the CCl4 group (Georges et 
al. 2007). Interestingly, LOX inhibition by BAPN can also reduce the mRNA expression of 
elastin (Jackson et al. 1991). Our observations further validate miR-29b as an antifibrotic 
therapeutics through inhibition of HSP47 and LOX. 
A unique feature of miRNA-mediated gene regulation is that individual miRNA can 
regulate hundreds of genes at the same time (Satoh et al. 2011). For example, SPARC (Zhu et 
al. 2012), BMP-1 (Luna et al. 2009) and fibronectin (Kadler et al. 2008) have been reported as 
target genes of miR-29b, and those molecules may also contribute to the altered fibril formation 
besides HSP47 and LOX. This property of miRNAs allows them to coordinate complex 
programs of gene expression to achieve similar consequences. Recently, Chou et al. (Chou et al. 
2013) reported that miR-29b can inhibit tumor metastasis by targeting LOX, LOXL2 and 
LOXL4 in breast cancer cells. This observation indicates the implication of miR-29b and LOX 
in the regulation of tumor microenvironment besides ECM synthesis. More studies are needed 
to better understand the regulation of each factor by miR-29 and their respective contribution to 
the altered ECM biosynthesis under various pathological conditions. Nevertheless, our 
observations strongly support a role of miR-29b in the regulation of ECM maturation during 
liver fibrosis. 
In conclusion, we have shown for the first time that miR-29b plays a role in collagen 
maturation. These data, together with other published works, suggest complex mechanisms by 
which miR-29 regulates ECM biosynthesis at multiple steps. Our data further indicates that 
miR-29 may become a promising therapeutic for the treatment of liver fibrosis. 
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4.0  FMOC-CONJUGATED PEG-VITAMIN E2 MICELLES FOR TUMOR-
TARGETED DELIVERY OF PACLITAXEL: ENHANCED DRUG-CARRIER 
INTERACTION AND LOADING CAPACITY 
4.1 BACKGROUND 
Paclitaxel (PTX) is a potent anticancer agent acting through the stabilization of microtubules 
(Horwitz 1994). However, the clinical benefit of PTX is limited by its poor water solubility. The 
widely-used clinical formulation Taxol® contains alcohol and Cremophor EL which can cause 
irritation and hyperactivity reactions (Soga et al. 2005). Therefore, substantial efforts have been 
made to develop alternative formulations to improve the solubility of PTX. Polymeric micelles 
have attracted significant attention due to their unique advantages for the intravenous delivery 
of paclitaxel and other hydrophobic drugs. The small size (10-100nm) of micelles and 
hydrophilic corona shells of PEG are critical for the long blood circulation time and effective 
passive targeting to tumor tissues through enhanced permeability and retention (EPR) effect 
(Gao et al. 2002), leading to enhanced antitumor efficacy and decreased toxicity. Several 
micelle formulations of PTX have been developed and hold great promise for clinical 
application, such as NK105 (PTX-loaded polyethylene glycol-(L-aspartic acid) micelles) (Kato 
et al. 2012) and Genexol-PM (a PTX incorporated PEG-PLA micelle system) (Kim et al. 2007). 
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D-alpha-tocopheryl polyethylene glycol (PEG)-1000 succinate (TPGS) is a PEG derivative of 
Vitamin E that has been used as an excipient in various drug formulations (Yu et al. 1999, Win 
et al. 2006, Cao et al. 2008, Muthu et al. 2011). TPGS has intrinsic P-gp inhibitory effect which 
helps to overcome multidrug resistance (Dintaman et al. 1999, Collnot et al. 2010). TPGS is 
self-assembled into micelles in aqueous solution, however, the high critical micelle 
concentration (CMC) decreases the stability of micelles in physiological environment (Mi et al. 
2011). By increasing the PEG length and including one additional VE chain, the PEG2K-VE2 
micelles achieved lower CMC value, higher loading capacity for doxorubicin and enhanced 
anticancer effect compared with PEG2K-VE and traditional TPGS (Wang et al. 2012a). We 
recently synthesized and compared four PEG-Vitamin E conjugates that differ in PEG 
molecular weight (2K vs. 5K) and the number of Vitamin E molecules (1 vs. 2) (Lu et al. 
2013a). PEG5K-Vitamin E2 (PEG-VE2) was shown to be the most stable and effective micellar 
formulation of PTX. The tumor growth inhibitory effect of PTX-loaded PEG5K-VE2 was 
significantly improved in comparison to Taxol formulation or other three PTX micellar 
formulations in vivo (Lu et al. 2013a). Nevertheless, the drug loading capacity of PTX-loaded 
PEG5K-VE2 micelles was still inadequate, which warranted further studies.  
We have recently shown that incorporation of a drug-interactive domain into a lipid 
surfactant can improve both drug-loading capacity and formulation stability. This concept was 
experimentally tested when we were formulating JP4-039, a mitochondria-targeted antioxidant. 
We have synthesized a series of PEG-lipopeptides that have a PEG hydrophilic headgroup, one 
or several oleoyl chains, and amino acids derivatized with various functional motifs at the 
interfacial region. Among several functional groups tested, 9-Fluorenylmethoxycarbony (α-
Fmoc) was identified to be the most effective drug-interactive motif that not only enhances the 
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JP4-039 loading capacity but also improves the stability of JP4-039-loaded emulsion and 
micellar formulations (Gao et al. 2013). The improved drug/carrier interaction can be attributed 
to the hydrophobic/hydrophobic interaction, hydrogen bonding, and π−π stacking between the 
Fmoc-containing carrier and JP4-039 (Gao et al. 2013).  
We hypothesize that inclusion of Fmoc moiety shall similarly improve the drug loading 
capacity of PEG5K-VE2 micelles for PTX. In the current work, we synthesized a novel 
amphiphilic polymer, PEG5K-(Fmoc)-VE2 (PEG-FVE2) by introducing an Fmoc motif into 
PEG5K-VE2 conjugate. To evaluate the ability of PEG-FVE2 micelles for loading PTX, the drug 
loading capacity of those micelles was investigated. The interaction between Fmoc moiety and 
PTX molecule was analyzed by measuring the change of Fmoc fluorescence intensity with 
different drug: carrier ratios. Cytotoxicity of blank micelles and PTX-loaded micelles was 
studied against free PTX using various tumor cell lines. Finally, the therapeutic efficacy and 
toxicity of PTX-loaded micelles were investigated using a syngeneic mouse model of breast 
cancer (4T1.2). 
4.2 METHODS 
4.2.1 Materials 
PTX (98%) was purchased from AK Scientific Inc. (CA, USA). Dulbecco’s phosphate buffered 
saline (DPBS) was purchased from Lonza (MD, USA). Methoxy-PEG5,000-OH, dimethyl 
sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium bromide (MTT), 
Triton X-100, Dulbecco’s Modified Eagle’s Medium (DMEM), succinate anhydride, Boc-lys-
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(Boc)-OH and Fmoc-lys-(Boc)-OH were all purchased from Sigma-Aldrich (MO, USA). Fetal 
bovine serum (FBS) and penicillin-streptomycin solution were from Invitrogen (NY, USA). D-
alpha-tocopheryl was purchased from Tokyo Chemical Industry (OR, USA). N,N'-
Dicyclohexylcarbodiimide (DCC) was purchased from Alfa Aesar (MA, USA). 4-
Dimethylaminopyridine (DMAP) was purchased from Calbiochem-Novabiochem Corporation 
(CA, USA). All solvents used in this study were HPLC grade. 
4.2.2 Synthesis of PEG5K-Fmoc-VE2 (PEG-FVE2) 
PEG-FVE2 was synthesized via solution phase condensation reactions from MeO-PEG-OH with 
a molecular weight of 5,000 Da. Fmoc-lys-(Boc)-OH (4 eq.) was coupled onto the terminal -OH 
of PEG using DCC (4 eq.) and DMAP (0.2 eq.) as coupling reagents in DCM for overnight. 
Fmoc-lys-(Boc) PEG ester was precipitated and washed three times with cold ethanol and ether, 
respectively. Then, Boc groups were removed by the treatment with 50% trifluoroacetic acid in 
DCM, and the Fmoc-lysyl PEG ester was precipitated and washed three times with cold ethanol 
and ether, respectively. Boc-lys-(Boc)-OH (2 eq.) was coupled onto the terminal -NH2 of Fmoc-
lysyl PEG ester using DCC (2 eq.) and DMAP (0.1 eq.) as coupling reagents in DCM for 
overnight. The di-Boc PEG ester was precipitated and washed three times with cold ethanol and 
ether, respectively. Then, Boc groups were removed by the treatment with 50% trifluoroacetic 
acid in DCM, and the di-NH2 PEG ester was precipitated and washed three times with cold 
ethanol and ether, respectively. The resulting white powder precipitate was dried under vacuum. 
Vitamin E succinate (4 eq.) was coupled to the deprotected amino groups of lysine with the 
assistance of DCC (4 eq.) and DMAP (0.2 eq.). The resulting PEG-FVE2 was precipitated and 
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washed three times with cold ethanol and ether, respectively. The final product was 
subsequently dialyzed against water and lyophilized to yield white powder. 
4.2.3 Preparation and characterization of PEG-FVE2 micelles 
Drug-free or PTX-loaded PEG-FVE2 micelles were prepared according to published procedures 
(Lu et al. 2013a). Briefly, PTX solution (10 mM in chloroform) was mixed with PEG-FVE2 (10 
mM in chloroform) at various molar ratios. The chloroform was removed by nitrogen flow and 
a thin dry film of drug/carrier mixture was formed. High vacuum was then applied to remove 
any traces of remaining solvent. DPBS was added into each vial to hydrate the film. The 
samples were then probe-sonicated for 2 min at 3 watts. The blank micelles were similarly 
prepared except that PTX was not added. 
 
The size of micelles was measured by dynamic light scattering (DLS) method using a 
Malvern Zetasizer (Nano ZS; Malvern instruments Ltd, Worcestershire, UK). The PTX 
concentration was kept at 1 mg/mL for DLS measurements. To observe the morphology of 
PEG-FVE2 micelles, the aqueous micelle formulation was deposited onto copper grids with 
Formvar and stained with 1% uranyl acetate. Imaging was performed at room temperature using 
transmission electron microscopy (TEM) (JEM-1011, JEOL, Japan) (Lu et al. 2013a). To 
measure the PTX loading efficiency, unincorporated free PTX was removed by filtering through 
a syringe filter with pore size of 0.22 µm (Lu et al. 2013b). The amount of PTX loaded into 
micelles was analyzed by HPLC according to a published method (Lu et al. 2013b). The drug 
loading capacity (DLC) and drug loading efficiency (DLE) were calculated according to the 
following formula (Lu et al. 2013b): 
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DLC (%) = [weight of drug used/(weight of polymer + drug used)] ×100% 
DLE (%) = (weight of loaded drug/weight of input drug) ×100%. 
4.2.4 CMC measurement 
The CMC of PEG-FVE2 was determined by employing pyrene as a fluorescence probe as 
described previously (Lu et al. 2013b). Briefly, aliquots of 50 µL pyrene solution (4.8×10-6 M) 
were mixed with various amount of PEG-FVE2 in chloroform. The chloroform was then 
removed by nitrogen flow and high vacuum to form a thin film in the vials. Each sample was 
hydrated with 400 µL DPBS to give a final pyrene concentration of 6×10-7 M with PEG-FVE2 
concentrations ranging from 6×10-5 to 0.25 mg/mL. The samples were kept shaking at 37 ? for 
24 h to reach equilibrium, followed by fluorescence measurement at the wavelength of em/ex= 
334 nm/390 nm using Synergy H1 Hybrid Multi-Mode Microplate Reader (Winooski, VT). The 
fluorescence intensity was plotted against PEG-FVE2 concentration. The CMC was determined 
from the threshold concentration, where the fluorescence intensity begins to increase 
dramatically. 
4.2.5 Fluorescence measurement of blank and PTX-loaded micelles  
Micelle formulations with or without PTX were prepared in 500 µL of water as 
described (Zhang et al. 2014). The fluorescence intensity was measured with a Synergy H1 
Hybrid reader (BioTek). The emission spectra were recorded ranging from 300-400 nm with a 
fixed excitation at 270 nm. 
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4.2.6 Hemolytic effect of micelles 
Rat blood was collected via cardiac puncture with heparin as the anticoagulant. The blood 
sample was centrifuged at 1500 rpm for 10 min at 4 ? to collect the red blood cells (RBCs). 
The RBCs were washed with 30 mL ice-cold DPBS for three times and diluted to 2% w/v with 
ice-cold DPBS. One mL of diluted RBC suspension was mixed with blank PEG-VE2 or PEG-
FVE2 micelles to obtain final polymer concentrations of 0.2 or 1.0 mg/mL. The mixture was 
incubated at 37 ? with constant shaking for 4 h and then centrifuged at 1500 rpm for 10 min at 
4 ?. One hundred µL of supernatant from each sample was transferred into a 96-well plate. The 
absorbance at 540 nm was measured using a PerkinElmer LS 50B luminescence spectrometer 
(Waltham, MA) at the wavelength of 540 nm to determine the release of hemoglobin from 
RBCs. Triton X-100 (2%) and DPBS were also incubated with RBCs as positive and negative 
controls, respectively. The percent of hemoglobin release was calculated as (ODsample-ODnegative 
control)/(ODpositive control-ODnegative control) × 100% (Lu et al. 2013b). 
4.2.7 Cell culture 
Huh-7 is a human hepatocellular carcinoma cell line and Hepa 1-6 is a mouse hepatoma cell 
line. 4T1.2 is a mouse metastatic breast cancer cell line. MCF-7 is a human breast cancer cell 
line. All cell lines were cultured in DMEM containing 10% FBS and 1% penicillin- 
streptomycin at 37 ? in a humidified incubator with 5% CO2. 
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4.2.8 In vitro cytotoxicity study 
The PTX-loaded PEG-FVE2 micelles were examined for their cytotoxicity against four cancer 
cell lines using PTX-loaded PEG-VE2 micelles, Taxol® formulation and PTX dissolved in 
DMSO as control groups. The 4T1.2 cells were seeded in 96-well plates at a density of 1000 
cells per well. After incubation for 24 h, the cells were treated with various formulations at the 
indicated PTX concentrations for 72 h, followed by MTT assay as described previously (Lu et 
al. 2013b).  Briefly, 20 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
(MTT) in DPBS (5 mg/mL) was added to each well and the cells were further incubated for 4 h. 
The medium was then removed and 150 µL DMSO was added into each well to solubilize the 
MTT formazan. The absorbance at 570 nm was detected by PerkinElmer LS 50B luminescence 
spectrometer (Waltham, MA). Data were shown as the percentages of cell viability calculated 
from triplicate wells using the formula: [(ODtreat − ODblank)/(ODuntreat − ODblank) ×100%]. The 
cytotoxicity with Huh-7, Hepa 1-6 and MCF-7 cells was similarly performed except that the 
cells were seeded at a density of 5000 cells per well. 
4.2.9 Animals 
Female BALB/c mice, 10-12 weeks and male Sprague-Dawley rats were purchased from 
Charles River Laboratories (Wilmington, MA). All animals were housed under pathogen-free 
conditions according to AAALAC guidelines. All animal-related experiments were performed 
in full compliance with institutional guidelines and approved by the Animal Use and Care 
Administrative Advisory Committee at the University of Pittsburgh. 
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4.2.10 In vivo anti-tumor therapeutic study 
A syngeneic murine breast cancer model was used to evaluate the therapeutic efficacy of PTX-
loaded PEG-FVE2 micelles. 2 x 105 4T1.2 cells in 200 µL PBS were inoculated s.c. at the right 
flank of female BALB/c mice. Treatments were initiated when tumors in the mice reached a 
volume around 50 mm3 and this day was designated as day 0. On day 0, mice were randomly 
divided into five groups (n=5) and treated with tail vein injection of saline (control), blank PEG-
FVE2 micelles, PTX-loaded PEG-VE2 micelles (PEG-VE2 : PTX=1:5, mol : mol), PTX-loaded 
PEG-FVE2 micelles (PEG-FVE2 : PTX=1:5, mol : mol) and Taxol® (all at 10mg PTX/kg). 
Blank PEG-FVE2 micelles were given at the equivalent dosage of the carrier in the group of 
PTX-loaded micelles. The treatment was performed three times a week for 2 weeks. Tumor size 
was measured with digital caliper three times a week. Tumor volume was calculated by the 
formula: (L×W2)/2, where L is the longest and W is the shortest in tumor diameters (mm). Mice 
were sacrificed at the end of experiment. To compare between groups, relative tumor volume 
(RTV) was calculated at each measurement time point (where RTV equals the tumor volume at 
a given time point divided by the tumor volume prior to the first treatment). Mice were 
euthanized when tumor volume reached 2000 mm3. To monitor potential toxicity, the body 
weight of each mouse was measured three times a week. In addition, serum levels of aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) were examined at the completion 
of the study. 
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4.2.11 Statistical analysis 
Statistical analysis was performed by Student’s t-test for two groups, and one-way ANOVA for 
multiple groups, followed by Newman-Keuls test if P < 0.05. All results were reported as the 
mean ± standard deviation (SD) unless otherwise indicated. A value of P < 0.05 was considered 
statistically significant. 
4.3 RESULTS 
4.3.1 Synthesis and biophysical characterization of PEG-FVE2 
PEG-FVE2 polymer was synthesized by conjugating PEG5K with Vitamin E succinate 
using dendritic oligo-lysine as the scaffold. Fmoc-lys-(Boc) and Boc-lys-(Boc) were 
sequentially linked to PEG5K by condensation reaction, followed by conjugation with succinate 
VE. The synthetic scheme is shown in Figure 22. The structure of PEG-FVE2 was confirmed by 
1H NMR (Figure 23A) and MALDI-TOF (Figure 23B). In Figure 23A, the peaks between 7.2 
ppm and 8.5 ppm were assigned to the Fmoc group. The peak at 3.3 ppm corresponded to the –
OCH3 on the end of mPEG, the intense peaks at 3.5 ppm could be assigned to the methane 
protons of the polyethylene glycol. The proton peaks below 3.0 ppm were assigned to the 
Vitamin E succinate. MALDI-TOF indicated that the molecular weight of PEG-FVE2 was 
around 6500 (Figure 23B), which is in agreement with the calculated molecular weight of 6502. 
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Figure 22 Synthesis scheme of PEG-FVE2 conjugate. 
 
The sizes of PTX-loaded PEG-FVE2 micelles at different carrier: drug molar ratios were 
determined by DLS analysis. The sizes of blank and drug-loaded micelles were both around 60 
nm (Table 2). PTX could be loaded into PEG-FVE2 micelles at a carrier: drug molar ratio as 
low as 0.5:1. This is in contrast to PEG-VE2 micelles for which a minimal carrier: drug molar 
ratio of 2.5:1 was required to solubilize PTX (Lu et al. 2013a). In addition, the drug loading 
efficiency as determined by HPLC was also improved by increasing the carrier: drug ratios. 
More than 95% of the input PTX was incorporated into the micelles at a carrier: drug molar 
ratio of 1:1 and above (Table 2).   
The morphology of PEG-FVE2 micelles was examined by TEM (Figure 24A-C). In 
aqueous solution, PEG-FVE2 self-assembled and formed a mixture of worm-like and spherical 
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structures in the absence of PTX (Figure 24A). Similar structures were observed for PTX-
loaded PEG-FVE2 micelles at various carrier: drug ratios (Figure 24B-C). This observation was 
in contrast to the PEG-VE2 without Fmoc moiety which formed uniform spherical micelles 
(Figure 24D).  
A 
 
B 
 
Figure 23 1H-NMR (A) in DMSO and Mass spectrum (B) of PEG-FVE2 
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Table 2 Characteristics of blank and PTX-loaded PEG-FVE2 micelles. 
micelle amolar ratio bSize (nm) cPDI dDLC (%) eDLE (%) 
PEG-FVE2 - 60.12±2.99 0.208 - - 
PEG-FVE2:PTX 0.5:1 55.32±1.84 0.256 20.8 87.0 
1:1 61.60±3.55 0.213 11.6 96.0 
2.5:1 68.64±2.90 0.224 5.0 95.4 
5:1 70.06±6.84 0.226 2.6 98.9 
 
aThe PTX concentration was 1mg/mL in all the drug-loaded samples above. 
bData represents the mean ± standard deviation (n=3) 
cPDI: Polydispersity index. 
dDLC: drug loading capacity  
eDLE: drug loading efficiency 
 
 
 
 
Figure 24 Typical TEM images of blank PEG-FVE2 micelles (A), PTX-loaded PEG-FVE2 micelles (B-C) and 
blank PEG-VE2 micelles (D).  
The PEG-FVE2 : PTX molar ratio was 1 : 1 (B) or 3 : 1(C). PTX concentration was kept at 1mg/mL. Bar = 100 nm. 
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The CMC of PEG-FVE2 polymer was measured with pyrene as the fluorescent probe. A 
series of pyrene-loaded PEG-FVE2 micelles were prepared with a fixed concentration of pyrene 
and different concentrations of polymer. When the concentration of a polymer reaches its CMC, 
the micellization is marked by an abrupt increase in fluorescence intensity of pyrene at the 
wavelength of 390 nm (Sezgin et al. 2007). Based on this principle, the fluorescence intensity 
was recorded and plotted against the logarithmic concentration of the PEG-FVE2 polymer, and 
the CMC value was determined. Figure 25 shows that the CMC of PEG-FVE2 micelles was 4 
µg /ml, which was slightly higher than that of PEG-VE2 (1.7 µg/ml) (Lu et al. 2013a), but still 
significantly lower than that of TPGS (0.2 mg/ml)(Mi et al. 2011). 
 
Figure 25 CMC determination of the PEG-FVE2 micelles using pyrene as a hydrophobic fluorescence probe.  
The fluorescence intensity of pyrene was measured (Ex/Em = 334nm/ 390nm) and plotted against the logarithmic 
concentration of PEG-FVE2 micelles. The concentration of pyrene was kept at 6 ×10-7 mol/L. Values reported are 
the means ± SD, n=3. 
4.3.2 Fluorescence quenching assay 
The improved PTX loading capacity of PEG-FVE2 over PEG-VE2 suggests a role of 
Fmoc/PTX interaction in the formation of PTX-loaded PEG-FVE2 micelles. To test this 
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hypothesis, we studied the Fmoc/PTX interaction via fluorescence quenching assay. We chose 
an excitation wavelength of 270 nm and examined the emission spectra of PEG-FVE2, PEG-
VE2 and free PTX ranging from 300 nm to 400 nm. As shown in Figure 26A, there is a distinct 
fluorescence peak at the emission wavelength of 305 nm for PEG-FVE2. This fluorescence 
appeared to be highly specific for Fmoc because minimal fluorescence intensity was detected 
for either PEG-VE2 or free PTX (Figure 26A). We then prepared several PTX-loaded PEG-
FVE2 micelles with constant PEG-FVE2 concentration but varying amounts of PTX, and 
similarly measured the fluorescence intensity. As shown in Figure 26B, the fluorescence 
intensity of Fmoc group at 305 nm was dramatically reduced with increased amount of PTX. 
We also conducted a similar experiment with several different mixed micelles that had a fixed 
concentration of PTX (0 or 0.1mg/mL) but varying amounts of PEG-FVE2. As shown in Figure 
26C, at each concentration of PEG-FVE2, the Fmoc fluorescence intensity at 305 nm was 
dramatically reduced in the presence of PTX. Figure 26D summarizes the changes of 
fluorescence intensity at 305 nm from the above fluorescence studies. It is apparent that the 
carrier: drug molar ratio affected the degree of reduction in fluorescence, which became more 
dramatic with increased amount of PTX. 
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Figure 26 Change of Fmoc fluorescence intensity in PEG-FVE2 loaded with various amount of PTX. 
The fluorescence emission spectra at 300-400 nm were recorded with a fixed excitation wavelength of 270 nm (A-
C). (B) Fluorescence spectra at different drug: carrier molar ratios with fixed concentration of PEG-FVE2 at 3.81 
mg/mL. (C) Fluorescence spectra at different drug: carrier molar ratios with fixed concentration of PTX at 
0.1mg/mL. (D) Summary of changes in the fluorescence intensity of various formulations in (C) at 305nm. 
4.3.3 Hemolytic effect of micelles 
The PEG-FVE2 polymer is amphiphilic and could solubilize lipids or insert into phospholipid 
membranes to induce membrane destabilization (Savic et al. 2003). Detrimental interaction 
between the polymeric materials and blood constituents such as red blood cells must be avoided 
for intravenous drug delivery. Therefore, the hemolytic effect of PEG-FVE2 micelles was 
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evaluated as an indicator of the hematocompatibility. Polyethylenimine (PEI), a cationic 
polymer with potent cell surface activity, was included as the positive control. As shown in 
Figure 27, incubation of RBC with PEI caused significant hemolysis in a concentration-
dependent manner. In contrast, with PEG-FVE2, the percentage of hemolysis was less than 5 % 
at both 0.2 mg/ml and 1mg/ml, which is considered as non-hemolytic according to the Guiding 
Principles of Hemolysis Test [H]GPT4-1 (Li et al. 2009b). These data suggest that the PEG-
FVE2 polymer is hemocompatible and suitable for intravenous administration. It is possible that 
the hemolytic effects differ between species; therefore, human blood will be used to further 
evaluate the hemolytic effect of PEG-FVE2 polymer in the future. 
 
Figure 27 Hemolytic activity of PEG-FVE2 compared to PEG-VE2 and PEI.  
The polymers (0.2 mg/mL or 1 mg/mL) were incubated with rat red blood cells (RBCs) for 4 h at 37 ? in an 
incubator shaker. The degree of RBCs lysis was determined by measuring the absorbance of solution at 540 nm 
after centrifuge. 2% Triton X-100 and DPBS were used as positive and negative control, respectively. Values are 
presented as means ± SD, n=3. 
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4.3.4 In vitro cytotoxicity of PTX-loaded micelles 
The cytotoxicity of PTX-loaded PEG-FVE2 micelles was investigated in breast cancer cell lines 
such as 4T1.2, MCF-7, and liver cancer cell lines including Hepa 1-6 and Huh-7 cells (Figure 
28A-D). PTX-loaded PEG-VE2 micelles, free PTX dissolved with DMSO, and Taxol were 
included as control formulations. PTX-loaded PEG-FVE2 and PEG-VE2 micelles showed 
comparable tumor cell killing effect in all of the cell lines tested (Figure 28A-D). In 4T1.2 
cancer cells, both PTX-loaded PEG-VE2 and PEG-FVE2 micellar formulations were more 
cytotoxic than free PTX, but less active than Taxol formulation (Figure 28A). However, the two 
PTX micellar formulations showed higher level of cytotoxicity than both Taxol and free PTX 
towards MCF-7 cells (Figure 28B), Hepa 1-6 cells (Figure 28C) and Huh-7 cells (Figure 28D).  
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Figure 28 In vitro cytotoxicity of free PTX, PTX-loaded  PEG-FVE2 micelles, PTX-loaded PEG-VE2 micelles 
and Taxol formulation against several cancer cell lines. 
4T1.2 (A), MCF-7 (B), Hepa 1-6 (C) and Huh-7 (D) cells were treated with various formulations for 72 h followed 
by MTT assay. Data are reported as mean ± SD, n=3. 
 
The IC50 of various formulations in the four tumor cell lines tested are summarized in Table 3. 
Carrier alone (PEG-FVE2 or PEG-VE2) showed minimal cytotoxicity at the concentrations used 
for PTX mixed micelles (Figure 29). 
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Table 3 The IC50 of various PTX formulations on 4T1.2, MCF-7, Hepa 1-6 and Huh-7 cell lines. 
IC50 (nM) Free PTX Taxol PEG-VE2/PTX PEG-FVE2/PTX 
4T1.2 40.4 ± 4.8 27.6 ± 3.8 35.0 ± 1.9 33.6 ± 2.2 
MCF-7 98.5 ± 22.6 42.9 ± 27.0 12.3 ± 4.6 8.1 ± 2.3 
Hepa 1-6 81.0 ± 12.8 54.3 ± 18.0 15.2 ± 0.9 16.5 ± 1.2 
Huh-7 23.4 ± 7.0 16.8 ± 3.9 5.4 ± 2.0 4.7 ± 1.4 
 
 
A                                                                       B 
 
Figure 29 Cytotoxicity of blank PEG-FVE2 and PEG-VE2 to 4T1.2 (A) and Hepa 1-6 (B) cells 
4.3.5 In vivo therapeutic study 
The in vivo tumor growth inhibitory effect of PTX-loaded PEG-FVE2 micelles was investigated 
in a syngeneic murine breast cancer model (4T1.2). As shown in Figure 30A, blank PEG-FVE2 
micelles showed minimal inhibitory effect on tumor growth compared with the control group 
treated with saline. Taxol exhibited moderate effect in inhibiting the tumor growth at the PTX 
dose of 10 mg/kg. In contrast, at the same PTX dose, a significant improvement in tumor 
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growth inhibition was achieved in the mice treated with PTX-loaded PEG-VE2 micelles. 
Furthermore, the antitumor effect of PTX-loaded PEG-FVE2 micelles was even higher than that 
of PTX-loaded PEG-VE2 micelles 
The toxicity of all of the formulations was evaluated by following their effects on animal 
behavior, body weight, as well as serum levels of AST and ALT. Mice treated with Taxol 
frequently showed transient apathy (Danhier et al. 2009) and decreased overall activity over 10 
min post-injection. This is likely caused by Cremophor EL and ethanol in the Taxol 
formulation. In contrast, there was no noticeable change in activity of mice after injection of 
PTX-loaded PEG-FVE2 micelles. No significant changes in body weight occurred in all of the 
groups (Figure 30B). In addition, serum levels of AST and ALT in the mice treated with PTX-
loaded PEG-FVE2 micelles were comparable to those in saline treated group (Figure 30C-D), 
suggesting the negligible toxicity of PTX-loaded PEG-FVE2 in vivo. 
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Figure 30 Antitumor activity and toxicity of PTX-loaded PEG-FVE2 micelles in vivo. 
(A) Enhanced antitumor activity of PTX formulated in PEG-FVE2 micelles in vivo. Balb/c mice were inoculated 
s.c. with 4T1.2 cells (2 x 105 cells/mouse). After the tumor volume reach 50 mm3, the mice received various 
treatments via tail vein injection three times a week for two weeks as indicated by arrows in the graph. Tumor 
volume was measured and plotted as relative tumor volume. (B) Change of body weights in mice receiving 
different treatments. The ALT (C) and AST (D) enzyme activity in serum was measured at the conclusion of 
experiment. Data are presented as mean ± SD. *p<0.05 versus Taxol treated mice. N=5. 
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4.4 DISCUSSION 
We have previously shown that inclusion of drug-interactive Fmoc moiety into a lipopeptide 
surfactant can dramatically enhance its ability for loading JP4-039, a poorly water-soluble 
antioxidant (Gao et al. 2013). In this study, we applied this concept in the optimization of PEG-
VE2 polymeric material and synthesized a novel compound PEG-FVE2. Here we demonstrated 
that PEG-FVE2 is more effective for the loading of PTX compared with PEG-VE2.  
Drug solubility in amphiphilic di-block copolymer micelles is affected by the 
compatibility between the drug and the micelle core (Latere Dwan'Isa et al. 2007). 
Accumulating data have demonstrated that the drug loading capacity and stability of micelles 
can be greatly improved by tailoring the inner core segment of micelles for stronger drug-carrier 
interaction. Besides hydrophobic interaction, the compatibility between drug and carrier was 
shown to be improved by various additional non-covalent bonding. For example, hydrogen-
bonding of micelles with doxorubicin significantly enhanced their loading capacity and stability 
(Kim et al. 2010c, Yang et al. 2012a). In addition, acid-base interaction between hydrophobic 
segments of micelles and guest molecules containing carboxylic acid groups also dramatically 
improved the loading of indomethacin and ibuprofen (Giacomelli et al. 2007). Furthermore, 
metal-ligand coordination facilitated the encapsulation of cisplatin into polymeric micelles 
(Yokoyama et al. 1996, Nishiyama et al. 2001). In particular, Park’s group showed that 
inclusion of “hydrotropic motifs” into the hydrophobic domain of polymeric micelles 
represented a versatile strategy to enhance the compatibility of carrier with poorly water-soluble 
drugs (Huh et al. 2005, Kim et al. 2011). Similarly, inclusion of aromatic end groups into the 
hydrophobic chain of di-block copolymers improved the stable incorporation of camptothecin 
(Opanasopit et al. 2004) and PTX (Carstens et al. 2008, Gao et al. 2013). Data from this study 
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and another recent study (Zhang et al. 2014) suggest that incorporation of a drug-interactive 
motif (Fmoc) at the interfacial region represents an effective strategy in improving the 
performance of lipid-core micellar systems in loading hydrophobic drugs such as PTX. 
Various mechanisms are likely to be involved in the carrier/drug interactions of PTX-
loaded PEG-FVE2 micelles, such as hydrophobic interaction with PTX, hydrogen bonding and 
the π- π stacking effect (Lu et al. 2013a). The enhanced PTX loading capacity was most likely 
due to excellent Fmoc-PTX compatibility, which results from the rigid aromatic structure of 
Fmoc moieties that may interact with those in PTX. This hypothesis was further supported by 
the change in Fmoc fluorescence intensity in the presence of PTX, which indicated the close 
proximity between Fmoc and PTX. The decrease of Fmoc fluorescence intensity likely results 
from the fluorescence quenching caused by intermolecular π-π interactions (Shirai et al. 1999). 
This information not only supports a role of Fmoc in the improved PTX loading capacity of 
PEG-FVE2 micellar system, but also sheds new light on the design of novel polymeric 
nanocarriers for the delivery of other aromatic structure-containing drugs such as doxorubicin. 
In contrast to the PEG-VE2 micelles that form typical spherical structures, PEG-FVE2 
micelles showed predominantly elongated, worm-like morphology. This might be attributed to 
the strong inter-molecular interaction among the PEG-FVE2 molecules mediated by Fmoc 
moieties. Fmoc is known to promote parallel interactions of individual short peptides carrying 
the same group, which often leads to the formation of elongated nanoassemblies (Gao et al. 
2013). It was reported that drug carriers with worm-like shape, also known as filomicelles, have 
shown longer circulation time compared with spherical nanoparticles composed of the similar 
materials, leading to improved drug accumulation in tumors (Geng et al. 2007, Christian et al. 
2009, Simone et al. 2009). Additional studies on the pharmacokinetic profile of PEG-FVE2 
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micelles would help to better understand the contribution of micelle morphology to their 
circulation time and tumor accumulation.  
MTT assay showed that the cytotoxicity of PTX-loaded PEG-FVE2 and PEG-VE2 
micelles was more potent than that of free PTX solubilized in DMSO in all the cell lines tested. 
In Hepa 1-6 and Huh-7 cells, the cell killing effect of PTX-loaded PEG-FVE2 and PEG-VE2 
micelles was even higher than that of Taxol formulation at the same PTX concentrations. This 
might be attributed to the increased cellular uptake of PTX into the cells due to the well-known 
p-gp inhibitory effect of Vitamin E derivatives (Dintaman et al. 1999, Lu et al. 2013a).  The fact 
that the cytotoxicity of PTX-loaded PEG-FVE2 micelles was similar or slightly higher than that 
of PTX-loaded PEG-VE2 micelles suggests that the PEG-FVE2 retained the function of PEG-
VE2 in enhancing the cellular uptake of drug-loaded micelles.  
A highly metastatic murine breast cancer cell line 4T1.2 was selected to investigate the 
in vivo therapeutic efficacy of PTX-loaded PEG-FVE2 micelles. PTX-loaded PEG-FVE2 
micelles demonstrated significantly higher tumor inhibitory effect compared with Taxol. The 
superior antitumor efficacy along with the minimal toxicity can be possibly attributed to a more 
effective EPR effect resulting from the PEG corona and the elongated shape of PEG-FVE2 
micelles (Geng et al. 2007), as well as enhanced intracellular uptake due to p-gp inhibition 
(Dintaman et al. 1999, Lu et al. 2013a). Further studies are currently ongoing in our lab to better 
understand the mechanism for the improved antitumor activity of PTX-loaded PEG-FVE2 
micelles.  
To date there is no report about how PEG-FVE2 conjugate is metabolized and eliminated 
in vivo. Theoretically, the ester bond can be cleaved, and the Fmoc group can be oxidized at 
certain positions, followed by conjugation with glucuronide or sulfate to become sufficiently 
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polar and readily excreted. In order to determine the metabolic fate of new chemical entities, the 
models most often used in vitro include: 1) metabolizing recombinant enzymes (e.g., CYP and 
UDP-glucuronosyltransferases); 2) subcellular fractions (e.g., microsomes, cytosols or S-9 
fractions); and 3) cellular organelles (e.g., hepatocytes and liver slices) (Jia et al. 2007). 
Analysis of the metabolites from incubation supernatants is required and usually accomplished 
by HPLC with mass spectrometry (Ackley et al., 2004). Investigation about metabolic pathway 
of PEG-FVE2 conjugate will be helpful to understand its potential biological effect on human 
body, which is required for FDA approval. 
In summary, we have shown that PEG-FVE2 possess higher loading capacity for PTX 
compared to PEG-VE2. This effect could be attributed to the high compatibility and interaction 
between PTX and Fmoc moiety. We have further shown that PTX-loaded PEG-FVE2 micelles 
led to significantly improved tumor inhibitory effect than Taxol with minimal toxicity in vivo. 
Our study suggests that incorporation of a drug-interactive motif (Fmoc) at the interfacial region 
represents an effective strategy to improve the performance of the micellar systems in loading 
poorly water-soluble drugs. 
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5.0  INCORPORATION OF A SELECTIVE SIGMA-2 RECEPTOR LIGAND 
ENHANCES UPTAKE OF LIPOSOMES BY MULTIPLE CANCER CELLS 
Background: Sigma-2 receptor is an attractive target for tumor imaging and targeted therapy, 
since it is over-expressed on multiple types of solid tumors including prostate cancer, breast 
cancer and lung cancer. SV119 is a synthetic small molecule which binds to sigma-2 receptors 
with high affinity and specificity. In this study we investigated the utility of SV119 in mediating 
selective targeting of liposomal vectors to various types of cancer cells. 
Methods: SV119 was covalently linked with polyethylene glycol-dioleyl amido aspartic acid 
conjugate (PEG-DOA) to generate a novel functional lipid, SV119-PEG-DOA. This lipid was 
utilized for the preparation of targeted liposomes to enhance their uptake by cancer cells. 
Liposomes with various SV119 density (0, 1, 3 and 5 mole%) were prepared and their cellular 
uptake was investigated with several tumor cell lines. In addition, doxorubicin (DOX) was 
loaded into targeted and unmodified liposomes, and the cytotoxic effect on DU-145 cells was 
evaluated by MTT assay. 
Results: Liposomes with or without SV119-PEG-DOA both have mean diameter of 
approximately 90 nm and neutral charge. Incorporation of SV119-PEG-DOA significantly 
increased the cellular uptake of liposomes by DU-145, PC-3, A549, 201T and MCF-7 tumor 
cells, as shown by both fluorescence microscopy and by quantitative measurement of 
fluorescence intensity. In contrast, the uptake of liposomes by normal BEAS-2B cells was not 
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increased by SV119. In a time course study, the uptake of SV119-liposomes by DU-145 cells 
also was significantly higher at each time point compared with unmodified liposomes. 
Furthermore, DOX-loaded SV119-liposomes showed significantly higher cytotoxicity to DU-
145 cells compared with DOX-loaded unmodified liposomes.  
Conclusion: SV119-liposomes were developed for targeted drug delivery to cancer cells. The 
targeting efficiency and specificity of SV119 liposomes to cancer cells was demonstrated in 
vitro. The results of this study suggest that SV119-modified liposomes might be a promising 
drug carrier for tumor targeted delivery. 
5.1 BACKGROUND 
One major problem with conventional anticancer agents is the severe side effects on normal 
tissues and organs. To solve this issue, targeted drug delivery to solid tumors was developed as 
an effective strategy to improve therapeutic effect and minimize toxicity. Success of targeted 
drug delivery is affected by many factors, including the choice of a targeting ligand.  Many 
types of ligands have been explored including antibodies, peptides, aptamers, and small 
molecule ligands (Wang et al. 2008a). Small molecule ligands have the advantages of minimal 
immunogenicity, excellent chemical stability and ease of synthesis (Wang et al. 2012b). Some 
examples of small molecule ligands that have been developed for tumor-targeting include 
ligands of folate receptor (Lee et al. 1995), prostate-specific membrane antigen (PSMA) 
(Moffatt et al. 2006), and integrin receptors (Zhang et al. 2010).  
Recently there has been increased interest in exploring sigma receptor ligands for tumor 
imaging and targeted therapy. The exact biological functions of sigma receptors are not fully 
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defined yet. Sigma-1 receptors functionally regulate ion channels belonging to various 
molecular families and have been shown to be involved in neuronal plasticity and central 
nervous system diseases. Recent studies have shown that sigma-2 receptor shapes cancer cell 
electrical signature upon environmental conditions (Crottès et al. 2013). An interesting 
possibility is that sigma and/or sigma-1 receptors could mediate anti-cancer effects by 
modulating ion channels (Aydar et al. 2004). Sigma receptors are over-expressed in a variety of 
human tumors including non-small cell lung carcinoma (NSCLC), prostate cancer, melanoma, 
and breast cancer. Small molecule ligands of sigma receptors have been developed and 
demonstrated potential as tumor imaging agents (John et al. 1999, Cobos et al. 2008, Maurice et 
al. 2009). We and Dr. Huang’s group reported that sigma receptor ligands such as anisamide 
effectively mediated selective delivery of liposomes containing doxorubicin (DOX) to prostate 
cancer cells in vitro and in vivo (John et al. 1993, Banerjee et al. 2004). Recently, extensive 
studies from Dr. Huang’s group demonstrated targeted delivery of oligodeoxynucleotides and 
siRNA to lung cancer and melanoma using anisamide-decorated nanoparticles (Li et al. 2006b, 
Li et al. 2008b, Nakagawa et al. 2010). In addition, another sigma receptor ligand haloperidol 
was shown to improve by more than 10-fold the transfection of MCF-7 breast carcinoma cells 
compared with control (unmodified) liposomes (Mukherjee et al. 2005). 
Both anisamide and haloperidol do not distinguish between sigma-1 and sigma-2 
receptor subtypes with respect to binding. In this study we examine if sigma 2-selective ligands 
can be employed for targeted delivery of liposomal vectors. There are several potential 
advantages with sigma 2-selective ligands for tumor-targeted delivery. First, there is a higher 
density of sigma-2 versus sigma-1 receptors in tumor samples and in cultured tumor cells 
(Vilner et al. 1995, Wheeler et al. 2000). Second, ligand binding and photoaffinity labeling 
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studies have demonstrated lower expression of sigma-2 vs. sigma-1 receptors in normal tissues 
from the central nervous system, gastrointestinal tract, kidney, liver and heart (Matsumoto et al. 
2007). Third, a correlation between sigma-2 receptor expression and tumor proliferation has 
been established both in vitro and in vivo (Mach et al. 1997, Colabufo et al. 2006), but such a 
correlation was not observed for the sigma-1 subtype.  
SV119 is a small molecule ligand that binds to sigma-2 receptors with high affinity and 
specificity (Kashiwagi et al. 2007). The tumor-targeting efficiency of SV119 has been 
demonstrated by conjugating SV119 with apoptosis-inducing peptides, resulting in selective 
killing of tumor cells (Spitzer et al. 2012). In the present study, the potential of SV119 to direct 
selective delivery of liposomes to multiple tumor cell lines was explored. Liposomes are well-
established drug carriers for intravenous delivery and several liposomal formulations have been 
approved for clinical applications (Di Paolo et al. 2008). Our results show that incorporation of 
a SV119 derivatized PEG-lipid significantly increased the cellular uptake of liposomes by 
several tumor cell lines but not by normal cells. In addition, DOX-loaded SV119-modified 
liposomes showed significantly higher cytotoxicity compared with unmodified liposomes 
loaded with DOX. These findings suggest that SV119-liposomes may have potential for 
targeting the delivery of anticancer agents to tumors that over-express sigma-2 receptors. 
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5.2 METHODS 
5.2.1 Materials 
L-α-phosphatidylcholine (Soy PC), DSPE-PEG(2000)-OCH3 and 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) 
(rhodamine-PE) were purchased from Avanti Polar Lipids (Birmingham, AL). Cholesterol 
(Chol), doxorubicin hydrochloride, FITC-conjugated anti-mouse IgG, 3- [4,5-dimethylthiazol-
2-yl]-2,5-diphenltetrazolium bromide (MTT) and dimethyl sulfoxide (DMSO) were purchased 
from Sigma–Aldrich (St. Louis, MO, USA). Mouse anti-early endosome antigen 1 (EEA1) 
monoclonal antibody was purchased from BD Transduction Laboratories. LysoTracker® Green 
DND-26 was purchased from Invitrogen, USA. PD-10 desalting column was purchased from 
GE Healthcare (Piscataway, NJ). Dulbecco`s Phosphate Buffered Saline (DPBS) was purchased 
from Gibco (Invitrogen Corporation, Carlsbad, CA). t-Boc Amine PEG NHS Ester (TBOC-
PEG-NHS, MW 3500) was purchased from JenKem Technology USA, Inc (Allen, TX). All 
other chemicals and organic solvents were purchased from Sigma-Aldrich. 1H NMR spectra 
were recorded on a Bruker FT 400 MHz. The synthesized compounds were also identified by 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry 
(Voyager-DE PRO BioSpectrometry Workstation, Applied Biosystems). The mass spectrum 
was obtained in linear mode with CHCA as the matrix. 
Human prostate adenocarcinoma cell line DU-145, human lung carcinoma cell line 
A549, and human breast cancer MCF-7 cells were obtained from American Type Culture 
Collection (Rockville, MD). BEAS-2B (human bronchial epithelium cell line) is a generous gift 
from Dr. Di, Y.P. Peter at University of Pittsburgh. Cells were cultured in DMEM medium 
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(ATCC) supplemented with 10% FBS (Invitrogen, Carlsbad, CA) and 1% penicillin-
streptomycin at 37°C in a humidified atmosphere of 5% CO2 in air. All reagents were from 
Sigma-Aldrich Corporation (St. Louis, MO) unless otherwise stated. 
5.2.2 Synthesis and Chemical Characterization of SV119-PEG-DOA Conjugates and 
Intermediates 
The synthetic procedure for preparing SV119-PEG-DOA is depicted schematically in 
Figure 32. Experimental details are delineated below. 
Compound 2. NaH (0.8 g, 60% in oil, 20 mmol) was added to a solution of 1 (3.04 g, 10 
mmol) and benzyl 2-bromoacetate (2.75 g, 12 mmol) in THF (50 mL) (Vangveravong et al. 
2006). The mixture was stirred overnight at ambient temperature. After the addition of ether (75 
mL), the organic solution was quenched with water (30 mL) and then washed with saturated 
NaCl solution (40 mL), and finally the organic solution was dried over Na2SO4. After removal 
of solvent, the crude product was purified by flash column chromatography with hexane-ethyl 
acetate(1: 1) to obtain 2 (4.33 g, 96%) as a pale yellow oil. 1H NMR (CDCl3) δ 7.98 (s, 1H), 
7.37-7.21 (m, 6H), 6.77 (m, 2H), 5.17 (s, 2H), 5.00 (m, 1H), 3.83 (s, 3H), 3.42 (m, 2H), 3.27 
(m, 2H), 2.33 (m, 2H), 2.30 (s, 3H), 2.13 (m, 1H), 1.98 (m, 2H), 1.51 (m, 3H), 1.17 (m, 2H). 
ESI-MS m/z 453.5 ([M+H]+). 
Compound 3. Chemical Name: 2-(3-((2-methoxy-5-methylphenyl)carbamoyl)-9-aza-
bicyclo[3.3.1]nonan-9-yl)acetic acid. Pd/C (10%, 500 mg) was added to a solution of 2 (3.62 g, 
10 mmol) and  stirred under 1 atm of H2 in MeOH (50 mL). After evaporation of the solvents 
under vacuum, EtOAc (100 mL) was added. The mixture was washed by saturated NaCl 
solution (40 mL), and finally the organic solution was dried over Na2SO4. EtOAc was then 
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removed to obtain 3 (2.82 g, 100%) as a white solid. 1H NMR (CDCl3) δ 10.9 (brs, 1H), 7.96 (s, 
1H), 7.15 (s, 1H), 6.79 (m, 2H), 4.96 (m, 1H), 3.83 (s, 3H), 3.32 (m, 2H), 3.04 (m, 2H), 2.35 
(m, 2H), 2.29 (s, 3H), 2.08 (m, 1H), 1.64 (m, 3H), 1.50 (m, 4H). ESI-MS m/z 363.4 ([M+H]+). 
Compound 4. A mixture of Boc-aspartic acid (2.47 g, 10 mmol), oleyl amine (8.01 g, 30 
mmol) and DCC (6.18 g, 30 mmol), DMAP (122 mg, 1 mmol) in anhydrous CH2Cl2 (60 mL) 
was stirred vigorously at room temperature for 5 h. After the reaction was completed, the 
mixture was filtered, and evaporated under reduced pressure, and the residue was purified by 
flash column chromatography (MeOH: CHCl3 1:9) to afford the product (4.40 g, 60%). 1H 
NMR (CDCl3) δ 7.93 (m, 1H), 5.37 (m, 4H), 4.17 (m, 1H), 3.24 (m, 4H), 1.98 (m, 9H), 1.51 (m, 
4H), 1.47 (s, 9H), 1.26 (m, 45H), 0.87 (m, 6H). ESI-MS m/z 719.1 ([M+H]+). 
DOA (dioleyl amido aspartic acid). To a solution of 4 (4.4 g, 6 mmol) in anhydrous 
CH2Cl2 (6 mL) was added trifluoroacetic acid (6 mL). After stirring for 2 h, the reaction mixture 
was diluted with CH2Cl2 (50 mL) and a saturated aqueous solution of Na2CO3 (20 mL) was then 
added until gas evolution ceased. The organic layer was separated and washed by brine. The 
organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash column chromatography (MeOH: CHCl3 1:9) to 
afford the product (3.70 g, 95%). 1H NMR (CDCl3) δ 7.53 (m, 1H), 6.33 (m, 1H), 5.37 (m, 4H), 
3.67 (m, 1H), 3.22 (m, 4H), 1.98 (m, 9H), 1.50 (m, 4H), 1.26 (m, 45H), 0.87 (m, 6H). ESI-MS 
m/z 641.0 ([M+Na]+). 
Compound 6. A mixture of Boc-NH2-PEG-NHS (350 mg, 0.1 mmol) and DOA (63.1 
mg, 0.1 mmol) in anhydrous CH2Cl2 (1 mL) was stirred vigorously at room temperature for 2 h. 
The solution was precipitated in cold diethyl ether and the precipitate was washed again by 
diethyl ether. Into the precipitate was added anhydrous CH2Cl2 (1 mL) and TFA (1 mL) and the 
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mixture was stirred for 2 h. The reaction mixture wan diluted with CH2Cl2 (10 mL) and a 
saturated aqueous solution of Na2CO3 (2 mL) was then added until gas evolution ceased. The 
organic layer was separated and precipitated in cold diethyl ether. The precipitate obtained was 
washed again by diethyl ether. 
Compound 7. A mixture of compound 3 (72 mg, 0.2 mmol), PEG-DOA (300 mg, 0.1 
mmol), DCC ( 41.2 mg, 0.2 mmol), and DMAP (12 mg, 0.1 mmol) in anhydrous CH2Cl2 (1 mL) 
was stirred vigorously at room temperature for 5 h. The solution was precipitated in cold diethyl 
ether and washed again with diethyl ether to obtain 7 (245mg, 73%).  
Compound 8. A mixture of compound 1 (304 mg, 1 mmol), succinic anhydride (200 mg, 
2 mmol), and DMAP (12 mg, 0.1 mmol) in anhydrous CH2Cl2 (1 mL) was stirred vigorously at 
room temperature for 5 h. The residue was purified by flash column chromatography (ethyl 
acetate) to afford the product. (3.70 g, 95%). 1H NMR (CDCl3) δ 10.9 (brs, 1H), 7.96 (s, 1H), 
7.15 (s, 1H), 6.79 (m, 2H), 4.96 (m, 1H), 3.83 (s, 3H), 3.04 (m, 2H), 2.72 (m, 2H), 2.35 (m, 
2H), 2.29 (s, 3H), 2.24 (m, 2H), 2.08 (m, 1H), 1.64 (m, 3H), 1.50 (m, 4H). 
Compound 9. A mixture of compound 8 (75 mg, 0.2 mmol), PEG-DOA (300 mg, 0.1 
mmol), DCC ( 41.2 mg, 0.2 mmol), and DMAP (12 mg, 0.1 mmol) in anhydrous CH2Cl2 (1 mL) 
was stirred vigorously at room temperature for 5 h. The solution was precipitated in cold diethyl 
ether and washed again with diethyl ether to obtain 9 (212mg, 65%). 
5.2.3 Preparation of rhodamine-PE labeled liposomes 
Rhodamine-PE labeled liposomes with or without SV119 were prepared by thin lipid film 
hydration followed by probe sonication. Unmodified liposomes were composed of 
SPC:Chol:DSPE-PEG2000:rhodamine-PE in a 7:3:0.5:0.05 molar ratio. Chloroform solution of 
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the lipid components was mixed and evaporated under a gentle stream of N2 followed by 
vacuum for at least 4 h. The dried lipid films were hydrated with DPBS at 4 °C overnight with 
an initial total lipid concentration of 16 mM. After brief vortex, the suspension was then probe 
sonicated for 1h at the power of 3 watts. Liposomes were then passed through a PD-10 desalting 
column and used for fluorescence microscopic and quantitative liposome uptake studies. The 
preparation of SV119-liposomes followed the same procedures except that DSPE-PEG2000 was 
partially substituted by DOA-PEG(3500)-SV119 conjugate. The size distribution and ζ-
potentials of the liposomes were monitored by dynamic light scattering method using the 
Malvern Zetasizer (Nano-ZS, Malvern Instruments Ltd., Worcestershire, UK). 
5.2.4 Cellular uptake studies 
Cells (2×104 per well) were seeded onto 48-well plates (Corning Inc., Corning, NY) and 
allowed to attach overnight. The complete medium was replaced with the serum-free DMEM 
containing rhodamine-PE labeled liposomes at a final total lipid concentration of 800 µM.  
Unmodified- or SV119- liposomes were incubated with cells at 37 °C for 1 h unless otherwise 
indicated. After incubation, the cells were then washed three times with ice cold PBS and lysed 
with 200 µl 0.3% Triton X-100 at room temperature for 0.5 h. Fluorescence intensity of cell 
lysate was determined by a Perkin-Elmer LS 50B luminescence spectrometer (Norwalk, CT) 
(lamda ex, 560nm;λ lamda emission, 588 nm). The results were expressed as arbitrary 
fluorescence intensity/mg of protein lysates. All the numbers were subtracted by the 
autofluorescence of cells incubated in serum-free medium without any formulations. The results 
are reported as the average values of four wells performed in the same plate on the same day.  
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glucose was mixed with the liposomes and incubated at 37°C for 20 min. The drug: lipid ratio 
was kept at approximately 100 µg/µmol to achieve an encapsulation efficiency of greater than 
90% (Eliaz et al. 2001). Nonentrapped DOX was removed by filtration through a PD-10 
column. After solubilization of the liposomes in 1% (w/v) Triton X-100, the DOX concentration 
in liposomes was determined by measuring the absorbance at 480 nm using free DOX solution 
as a standard. 
5.2.6 Cytotoxicity assay 
The viability of cells treated by DOX encapsulated in SV119-liposomes or unmodified 
liposomes was measured by MTT colorimetric assay. DU-145 cells were trypsinized and 
resuspended in serum-free DMEM. Formulations were diluted in serum-free medium and mixed 
with DU-145 cell suspension, followed by incubation at 37 °C for 1h. Then the medium was 
removed by centrifugation. The cell pellets were resuspended in complete medium and plated 
on a 96-well plate at a density of 5×103 cells per well.  Cells were cultured at 37 °C for another 
72 h followed by MTT assay. Twenty microliters of MTT solution (5 mg/mL in PBS) was 
added to each well and the cells were incubated for 4 hr at 37°C. Then the media were removed 
and 150 µl DMSO was added to each well. Absorbance at 550/630 nm was measured in 
Ultramark Microplate Imaging System (Bio-Rad, Hercules, CA). Six wells were used for each 
sample, and the data are expressed as the percentage of viable cells compared to untreated 
control cells. 
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5.2.7 Intracellular localization 
DU-145 cells grown on glass bottom dishes (In Vitro Scientific, Sunnyvale, CA) to 60%-70% 
confluence were incubated with rhodamine-PE labeled liposomes (with 3 mole% SV119-PEG-
DOA) at 37°C for 3 h or 16 h. For detection of early endosomes, the cells were fixed with 4% 
paraformaldehyde and permeabilized with 0.2% saponin, stained with anti-EEA1 (1:100) 
followed by FITC-conjugated anti-mouse IgG (1:100). For live cell staining of lysosomes, 
Lyso-Tracker Green® (50 nM) was added to the medium 30 min before the conclusion of 
incubation. The stained cells were rapidly washed with ice cold PBS and observed using an 
Olympus FV1000 laser scanning confocal microscope (Olympus America Inc., Melville, NY). 
5.2.8 Statistical analysis  
Statistical analysis was done by two-tailed unpaired Student’s t-test using the SPSS 
software, version 11.5 (SPSS. Inc., Chicago, IL) and data were expressed as mean ± SD. 
Differences with p < 0.05 were considered significant. 
5.3 RESULTS 
5.3.1 Synthesis of SV119-PEG3500-DOA 
In order to develop lipid-based nanoparticles incorporating SV119 on the surface, we 
have designed and synthesized a SV119-derivatized PEG-lipid. DOA is a double-chain lipid 
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5.3.2 Preparation of rhodamine-PE labeled liposomes 
The synthesized SV119-PEG-DOA was used to formulate targeted liposomes. 
Liposomes are mainly composed of phospholipids and cholesterol. These molecules also are 
components of the cells and, thus, are believed to be biocompatible and non-toxic. In our 
experiment, it was shown that all the liposomal formulations have a mean diameter of 
approximately 90 nm (Table 4), which is optimal for penetrating the blood vessels surrounding 
the tumor and subsequent endocytosis by the tumor cells (Gabizon 1995).  
 
Table 4 Size and zeta potential of SV119 decorated liposomes 
SV119-PEG-DOA 0% 1% 3% 5% 
Particle size (nm) 90.0 ± 0.2 90.7 ± 0.3 97.6 ± 0.2 89.2 ± 0.6 
Zeta Potential (mV) -2.0 ± 0.6 -2.4 ± 0.5 -2.2 ± 0.3 -3.1 ± 0.4 
Note: Data are the mean ± standard deviation for n=3. 
5.3.3 Cellular uptake studies 
The targeting efficiency of SV119-liposomes was characterized in vitro. Cellular uptake was 
studied using DU-145 cells as target cells. DU-145 is a human prostate cancer cell line and 
these cells have been reported to over-express sigma-2 receptors (John et al. 1999). Human 
bronchial epithelial cells BEAS-2B were chosen to examine the liposomal uptake by normal 
cells. SV119-PEG3500-DOA was formulated into rhodamine-PE labeled liposomes to partially 
substitute PEG2000-DSPE, and the total amount of PEG-conjugated lipid in liposomes was kept 
at 5 mole percent. A longer spacer (PEG3500) was used between SV119 and DOA to minimize 
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the potential steric hindrance imposed by DSPE-PEG2000 and to increase the targeting 
efficiency (Zhou et al. 2002a). 
Figure 36A shows the fluorescence images of DU-145 cells that were treated with 
rhodamine-PE labeled SV119-liposomes. After incubation with SV119-liposomes and 
unmodified liposomes for 1h, fluorescence was observed both on the cell membrane and inside 
the cells. Increasing the amounts of SV119 incorporated into the liposomes was associated with 
significant increase in rhodamine fluorescence intensity. This is in contrast to unmodified 
liposomes which showed minimal binding and cellular uptake by DU-145 cells (Figure 36A). 
Figure 36B shows the quantitative measurements of cell-associated fluorescence 1 h following 
treatment of DU145 cells with SV119-liposomes and unmodified liposomes. Consistent with 
the fluorescence imaging studies (Figure 36A), the amount of cell-associated fluorescence for 
DU-145 cells increased significantly with increasing amounts of ligand incorporated into the 
liposomes.  
In addition, binding and uptake of SV119-liposomes was competitively blocked by the 
presence of SV119-PEG550 conjugate, but was not inhibited by the same concentration of 
PEG550 (Figure 37). These results demonstrate that the enhanced uptake of SV119-liposomes 
was mediated by SV119. 
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liposomes were largely accumulated in the lysosomes, as evident by co-localization with 
markers of lysosomes (LysoTracker®; Figure 42D-F). These observations are consistent with 
the internalization via the endocytosis pathway. Future studies are warranted to improve the 
formulation to achieve more efficient release from endosomes and lysosomes. 
5.3.5 Cytotoxicity of DOX-loaded liposomes 
After demonstrating the efficiency and specificity of SV119 in mediating the uptake of 
liposomes by tumor cells, we investigated the utility of the SV119-liposomes for targeted 
delivery of anticancer agents. We chose DOX as the model drug since its liposomal formulation 
Doxil® is well-established and widely used in clinical chemotherapy. DU-145 cells were pre-
treated with DOX-loaded SV119-liposomes (SV119-L[D]), DOX-loaded unmodified liposomes 
(L[D]) and free DOX for 1h, and the cells were then cultured for an additional 72 h before 
conducting the MTT assay. Results show that the cytotoxic effects of all treatments were dose-
dependent at concentrations of 0.2~10 µg/mL (Figure 43). At each indicated concentration, the 
viability of cells treated with L[D] showed 1.5-3 folds enhancement compared with that of free 
DOX, suggesting the protection of the cells by encapsulation of the drug into liposomes. In 
addition, SV119-L[D] exhibited a ~2-fold higher cytotoxicity to DU-145 cells than L[D] 
(Figure 43), suggesting improved efficacy of the SV119-modified liposomes vs. unmodified 
liposomes for delivering DOX to the tumor cells.  The increased cytotoxicity of SV119-L[D] is 
consistent with the enhanced uptake of SV119-liposomes as shown in Figure 36. This 
demonstrates the potential of SV119-liposome to be used as a carrier for the targeted delivery of 
chemotherapeutics to tumor cells. 
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linker group of 6 methylene units. SAR studies suggest that the amino group is a preferred 
substituent for assuring a high affinity for σ2 receptors and high σ1 : σ2 selectivity. 
Nevertheless, various SV119 conjugates were synthesized by chemical modification of this 
amino group. For example, coupling of SV119 to a fluorescence molecule via this amino group 
lead to the development of a sigma-2-selective probe, SW-120,  which was used as an effective 
tool for the assessment of sigma-2 receptor expression levels in cultured tumor cells (Xu et al. 
2011). In addition, a recent study by Spitzer et al showed that coupling of SV119 to a 
proapoptotic peptide via the amino group similarly led to the development of a conjugate that 
demonstrated selective cytotoxicity towards tumor cells that overexpress sigma-2 receptor 
(Spitzer et al. 2012).   
We have demonstrated successful synthesis of the functional lipid, SV119-PEG-DOA, 
as well as its incorporation into a liposome formulation for targeted delivery to cancer cells. As 
compared with unmodified liposomes, the SV119-liposomes demonstrated enhanced uptake by 
multiple types of tumor cell lines including DU-145, MCF-7, PC-3, 201T and A549 cells. In 
addition, this enhanced uptake was shown to be dependent on ligand density and incubation 
time, and the uptake of SV119-liposomes was dramatically inhibited by the presence of free 
SV119. In contrast, enhanced uptake of SV119-liposomes was not observed in BEAS-2B 
normal cells, suggesting that enhanced uptake is specific for tumor cells. Furthermore, results of 
the MTT assay suggest that the incorporation of SV119 onto the surface of liposomes 
significantly enhanced the delivery and cytotoxicity of liposomal DOX in vitro.  Recently, Xia 
and colleague reported that SV119 mediated selective delivery of SV119-gold nanocage 
conjugates to tumor cells (Wang et al. 2012c). Collectively, these data suggest that SV119-
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conjugated nanoparticles may represent a promising delivery system for the targeted delivery of 
anticancer therapeutics to tumor cells. 
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6.0  SUMMARY AND PERSPECTIVES 
6.1 The role of miR-29 in liver fibrosis 
Liver fibrosis is a chronic disorder that is characterized by an alteration of the balance between 
fibrogenesis and fibrolysis, resulting in accumulation of excessive amounts of extracellular 
matrix (ECM) and distortion of the normal liver architecture. The activation and transformation 
of quiescent hepatic stellate cells (HSCs) into myofibroblast-like cells constitute a major 
mechanism for the increased production of ECM in the liver. The nuclear receptor farnesoid X 
receptor (FXR) shows potent antifibrotic activity in HSCs and protects animals in rodent 
models of liver fibrosis. However, the detailed mechanism remains incompletely understood. 
We report in this study that treatment with GW4064, a synthetic FXR ligand, led to 
upregulation of microRNA-29a (miR-29a) in HSCs isolated from wild-type mice, rats, and 
humans but not from FXR-/-mice. MiR-29a appears to play an inhibitory role in the regulation 
of ECM production as: 1) transfection of HSCs with miR-29a mimic resulted in drastic 
downregulation of the mRNA expression of a number of genes encoding ECM proteins; and 2) 
miR-29a significantly inhibited the expression of a reporter expression plasmid that contains the 
3’-UTR of the corresponding ECM genes. My results suggest that miR-29a is a FXR target gene 
because miR-29a promoter activity was significantly increased by pharmacological or genetic 
activation of FXR. Functional analysis of human miR-29a gene promoter identified an 
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imperfect inverted repeat DNA motif, IR1 (-AGGTCAcAGACCT), as a likely FXR-responsive 
element that is involved in miR-29a regulation. Our study uncovers a new mechanism by which 
FXR negatively regulates the expression of ECM in HSCs. 
Altered expression of miR-29b is implicated in the pathogenesis and progression of liver 
fibrosis. We and others previously demonstrated that miR-29b down-regulates the expression of 
several extracellular-matrix (ECM) genes including Col 1A1, Col 3A1 and Elastin via directly 
targeting their 3'-UTRs. However, whether or not miR-29b plays a role in the post-translational 
regulation of ECM biosynthesis has not been reported. Heat shock protein 47 (HSP47) and lysyl 
oxidase (LOX) are known to be essential for ECM maturation. In this study I have demonstrated 
that expression of HSP47 and LOX was significantly up-regulated in culture-activated primary 
rat HSCs, TGF-β stimulated LX-2 cells and liver tissue of CCl4-treated mice, which was 
accompanied by a decrease of miR-29b level. In contrast, over-expression of miR-29b in LX-2 
cells resulted in significant inhibition on HSP47 and LOX expression. Mechanistically, miR-
29b inhibited the expression of a reporter gene that contains the respective full-length 3'-UTR 
from HSP47 and LOX gene, and this inhibitory effect was abolished by the deletion of a 
putative miR-29b targeting sequence from the 3'-UTRs. Transfection of LX-2 cells with miR-
29b led to abnormal collagen structure as shown by electron-microscopy, presumably through 
down-regulation of the expression of molecules involved in ECM maturation including HSP47 
and LOX. These results demonstrated that miR-29b plays a role in regulating the post-
translational processing of ECM and fibril formation. 
The study of miRNAs and their roles in physiology and diseased processes has become a 
rapidly evolving field, as evidenced by the increasing body of literature. However, our 
understanding of how miRNAs function in liver diseases remains limited. MiRNAs are only one 
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class of regulatory molecules in the cells; there are many transcriptional factors and nuclear 
receptors that are also involved in gene regulation. How the regulatory networks amongst 
miRNAs, transcription factors, and their target genes are governed is just beginning to be 
discovered and understood. As discussed before, FXR activation can lead to upregulation of 
miR-29a, which is one of the major effectors to downregulate fibrosis-related genes. This 
reflects the complicated interaction of different regulatory machineries in controlling important 
physiological and pathophysiological events. 
It has become increasingly apparent that miRNA analysis may aid in disease diagnosis  
as well as the prediction of drug response and prognosis. Therapeutic applications using miRNA 
overexpression or downregulation may also represent a new strategy for the treatment of 
various diseases including liver diseases. MiRNAs are small molecules comprised of a known 
sequence that is often completely conserved among species, and these features are very 
attractive from a drug development standpoint. However, several issues need to be considered 
before the microRNA therapeutics enter the clinic. Firstly, safety is an important concern in 
drug development. In order to minimize the potential off target effects, the miRNAs that are 
more tissue restricted will be preferred, especially for chronic diseases. For example, inhibition 
of a hepatic-specific miRNA, miR-122, by LNA-anti-miR was shown to be safe and efficacious 
in the treatment of HCV-induced liver pathology. Secondly, intravenous gene delivery has to 
overcome three barriers at blood circulation, cellular and intracellular level, which include: (1) 
to decrease non-specific interactions with blood components and increase stability of 
microRNA in blood circulation; (2) to enhance the binding and uptake of microRNAs to the 
appropriate tissue or cells; and (3) effectively trigger the release of delivered microRNA from 
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endosomes to cytoplasm. These challenges will hopefully be addressed by appropriate design of 
delivery systems for microRNAs (Li et al. 2013b). 
It is generally believed that a single miRNA can potentially regulate hundreds of target 
mRNAs due to the fact that the primary target recognition determinant is only seven to eight 
nucleotides long in the seed region. This notion was further validated by a transcriptome 
analysis of tissues isolated from mice with targeted deletion of miRNAs. Thus, the potential off-
target of miRNA therapeutics needs to be thoroughly examined in animal and human studies. 
Liver cirrhosis is the leading cause of hepatocellular carcinoma (HCC), which is the fifth 
most common cancer in the world. Thus the second half of my dissertation work was mainly 
focused on the development of nanocarriers for tumor-targeted drug delivery. 
6.2 Tumor-targeted drug delivery with micelles 
Paclitaxel (PTX) is a potent chemotherapeutic agent, however, the clinical application of PTX is 
often limited by its poor water solubility and the toxicity of solubilizers used in its formulation. 
Many stable and non-toxic formulations of PTX such as PEG-derivatized Vitamin E polymeric 
micelles have been developed, which exhibit favorable biological activity in addition to 
solubilizing PTX. We have previously developed a series of PEG-Vitamin E conjugates with 
various lengths of PEG and different number of Vitamin E chains, among which the PEG5K-VE2 
has been shown to be the most effective PTX micellar formulation. However, the PEG5K-VE2 
formulation is still limited by the insufficient drug loading. Herein we report that the loading 
capacity for PTX could be significantly improved via incorporation of a drug-interactive motif 
(Fmoc) into the system. The PEG5K-(Fmoc)-VE2 (PEG-FVE2) micelles have a low CMC value 
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of 4 µg/ml and show a morphology of both spherical and worm-like structures on electron 
microscope. The Fmoc/PTX physical interaction was demonstrated by a fluorescence quenching 
assay. PTX-loaded PEG-FVE2 micelles exerted more potent cytotoxicity than free PTX or 
Taxol formulation in several tumor cell lines. Finally, intravenous injection of PTX-loaded 
PEG-FVE2 micelles showed superior anticancer activity and minimal toxicity compared with 
Taxol formulation in a mouse model of breast cancer. 
Polymeric micelles have been extensively studied over the last decade as versatile and 
efficient drug delivery systems for cancer therapy. The design of polymer structure is 
increasingly sophisticated to improve the drug loading capacity, tumor-specific uptake as well 
as anticancer effect. Various strategies have been developed to increase the drug/carrier 
interaction of polymeric micelles to maximize the drug loading capacity, such as hydrotropic 
polymers and Fmoc-conjugated surfactants. In addition, several biologically active carriers have 
been developed as dual-functional carriers to improve the anticancer effect. More systematic 
studies on the structure-activity relationship of polymeric micellar systems are needed to better 
understand the mechanism of drug-carrier interaction and the effect of polymer structure on the 
drug loading capacity. In addition, computational modeling may offer help in the tailored design 
of a polymeric carrier for each drug. These studies shall lead to the development of further 
improved micellar systems to advance the treatment of cancers. 
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APPENDIX A 
SEQUENCES OF PRIMERS FOR AMPLIFICATION OF 3'-UTR AND REAL-TIME 
PCR 
Gene  Forward primer  Reverse primer 
Col1A1 3'-UTR  ACGAGCTCAAACTCCCTCCATCC
CAATC 
ACACGCGTCCACCCCAGGGATA
AAAACT 
Mutated Col1A1 3'-UTR ACGAGCTCAAACTCCCTCCATCC
CAATC 
ACACGCGTATGGCCAGGCTTTG
ACCATTTG 
Col3A1 3'-UTR  ACGAGCTCTTATAAGCCAAACTC
TCTGAAAC 
ACACGCGTTGATGTTTATTTATT
ATATCACCATTA 
Mutated Col3A1 3'-UTR  ACGAGCTCTTATAAGCCAAACTC
TCTGAAAC 
ACACGCGTGAGACAGGGTGAAG
TTGGAATTGG 
ELN1 3'-UTR  ACACGCGTCTGACTCGCGACCTC
GTCA 
ACAAGCTTCACAGCGAAACACA
AAGAGG 
Mutated ELN1 3'-UTR  CCCACGCGTGGGGGTGCTACTGC
TTGGTGGAG 
CGAAGCTTCGCACCAATTTCTCT
TGGAGATGG 
miR-29a  TAGCACCATCTGAAATCGGTTA UNIVERSAL PRIMER 
rno-mir-29a precursor  CCCTTAGAGGATGACTGATTTC AACCGATTTCAGATGGTGCT 
rno-mir-29b precursor  GGAAGCTGGTTTCACATGGT TCCTAAAACACTGATTTCAAATG
G 
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rno-mir-29c precursor  ACACAGGCTGACCGATTTCT CCCCTACATCATAACCGATTTC 
hsa-mir-29a precursor  TGACTGATTTCTTTTGGTGTTCA AACCGATTTCAGATGGTGCT 
mmu-mir-29a precursor  CCCTTAGAGGATGACTGATTTC AACCGATTTCAGATGGTGCT 
Mus-HSP47 TGAACGCCATGTTCTTTAAGC AGTATAGGAGCGGGTCACCA 
Mus-LOX GGAGGACACGTCCTGTGACT CTGCCGCATAGGTGTCATAA 
Rat-HSP47 CTGCCTGAGAGCGAGTGTC AGGTGCCCAGAAGGAGAGAG 
Rat-LOX GCAAGCTTCTGTCTGGAGGA TCATAACATCCGGGACTCAA 
Homo-HSP47 GATGGGGAAGATGCAGAAGA CTTGTCAATGGCCTCAGTCA 
Homo-LOX TCCTGTGACTATGGCTACCAC GGCAGTCTATGTCTGCACCA 
HSP47 WT 3'-UTR CGACGCGTCGCTCAGGGTGCACA
CAGGAT 
CCCAAGCTTGGGCTTCCACGCTC
CAACAAAAT 
HSP47 Mut 3'-UTR CGACGCGTCGGTGAGGTACCAGC
CTTGGAT 
CCCAAGCTTGGGCTTCCACGCTC
CAACAAAAT 
LOX WT 3'-UTR CGAGCTCGATGGACACATCTGGT
GCTGA 
CGACGCGTCGAAGATTTAATGC
ATTTTACATTCAGA 
LOX Mut 3'-UTR-L CGAGCTCGAAACACATTACCATT
GGTGTCAA 
ACGTACTACGTGTAATTTCATTT
TCTTGAATTTAGGT 
LOX Mut 3'-UTR-R CGTAGTACGTTCTCAAGTAAGAT
TTTCCAGTGC 
CGACGCGTCGGCTTAGAGGATA
AATGAAATGTTTAGT 
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